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1 Introduction 
1.1 Macrophage migration inhibitory factor 
1.1.1 MIF – An Overview 
While developing an assay to measure the migration of peritoneal cells in 
capillary tubes, macrophage migration inhibitory factor (MIF) was 
discovered in 1962 (1). The first function contributed to MIF was its 
inhibitory action on the random migration of macrophages (2), and in the 
following years, MIF was shown to activate macrophages leading to their 
increased cell surface adhesion and phagocytosis (3). The molecular 
mechanisms underlying MIF’s functions nevertheless remained unknown. 
In 1989, a human MIF cDNA was first isolated and cloned, and the 
expressed polypeptide had the expected molecular weight of 12.5 kDa (4). 
Bernhagen et al. first cloned and purified murine MIF as a protein 
released from anterior pituitary cells in response to bacterial 
lipopolysaccharide (LPS) (5, 6). Soon macrophages were also described as a 
major source of MIF; they were observed to release MIF after stimulation 
with pro-inflammatory stimuli such as LPS, tumor necrosis factor (TNF) α 
and interferon (IFN) γ, and even after stimulation with low concentrations 
of anti-inflammatory glucocorticoids (7, 8). In 1999, a MIF knockout mouse 
was constructed, showing that the deletion of the mif gene reduces 
inflammatory responses (9). The discovery of the MIF cell surface receptor 
CD74 (10), and later of the chemokine receptors CXCR2 and CXCR4 (11), 
helped to improve the understanding of the molecular mechanism of MIF, 
and reports about an association of high expression MIF alleles and 
severity of inflammatory diseases further emphasized its role in disease 
pathology (12-14).   
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1.1.2 MIF in Inflammatory Disease 
Inflammation is the characteristic immune response of tissue to harmful 
stimuli. It is a protective attempt to remove the injurious stimulus and 
start the healing process. Causes for inflammation can be of physical 
(mechanical, thermal, radiation), chemical (toxins, acids, allergens) or 
biological (bacteria, viruses, parasites, fungi) nature.  
There are two types of inflammation: acute and chronic. Acute 
inflammation displays the five classic signs of inflammation: swelling, 
redness, pain, heat, and loss of function. In contrast, chronic inflammation 
does not show these symptoms, but is characterized by concurrent 
inflammation, tissue destruction, and attempts at repair (15). MIF is an 
important mediator in both acute and chronic inflammation. It was shown 
to be a key mediator in the pathogenesis of endotoxemia/sepsis, arthritis, 
glomerulonephritis, atherosclerosis, inflammatory bowel disease and 
several other inflammatory and immune conditions (16).  
MIF is a ubiquitously expressed protein that is most notably present in 
tissue that is in direct contact with the host’s environment including 
endothelial cells, and fibroblasts, the gastrointestinal tract, pituitary 
glands, kidney, liver, lung, pancreas, skin and eyes. Immune cells are the 
major source of circulating MIF, with monocytes/macrophages as the main 
contributor, followed by T cells and dendritic cell. B cells, neutrophils, 
eosinophils, basophils, and mast cells also release MIF (17).  
The release of MIF is a common occurrence in inflammatory diseases, for 
example the level of MIF is 5 – 10 times higher in serum of patients with 
rheumatoid arthritis compared to a healthy control group (18). Table 1 lists 
known stimuli causing the release of MIF.  
 
Table 1: Stimuli responsible for MIF release. Table adapted from (17). 
Stimulus Cell type 
Endotoxin Monocytes/macrophages, 
neutrophils, dendritic cells 
Exotoxin Macrophages, splenocytes 
Peptidoglycan PBMCs 
Heat killed E. coli PBMCs 
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Heat killed S. aureus PBMCs 
M. tuberculosis Macrophages 
Influenza virus Pulmonary epithelial cells 
TNF-α, INFγ Macrophages 
C5a Eosinophils, neutrophils 
IL-5 Eosinophils 
IL-9 Mast cells 
Nitric oxide Fetal membranes 
Anti-CD3 antibodies T cells 
Low-dose glucocorticoids Monocytes/macrophages, T cells 
 
 
1.1.2.1 Endotoxemia and Sepsis 
MIF is rapidly released by specialized pathway from pre-formed pools in 
immune and pituitary cells after stimulation with LPS, a virulence factor 
in the cell wall of gram-negative bacteria (5, 8, 19).  
In a murine model of endotoxemia, MIF was rapidly released after 
intraperitoneal injection of LPS, and peaked 8 – 20 h after stimulation. 
The concurrent administration of recombinant MIF protein and LPS 
decreased the survival rate compared to the control group (5). Moreover, 
neutralizing MIF via antibodies, the deletion of the mif gene, or the 
administration of small molecule MIF inhibitor prior to LPS challenge 
improved the chances for survival significantly (5, 9, 20). These results are 
in accord with models of E. coli injection in the peritoneum or cecal 
ligation and puncture (CLP). Peritonitis leads to an increased MIF level in 
the serum and treatment with anti-MIF antibodies has a protective effect 
(21).  
Of note, if mice with sublethal peritonitis had a secondary infection with 
S. typhimurium, P. aeruginosa, or L. monocytogenes 48 h after the first 
infection, the administration of recombinant MIF had a protective effect, 
whereas applying anti-MIF antibody further enhanced the negative effect 
of bacterial superinfection. This indicates that MIF has an important 
regulatory role in the inflammatory response, with likely a positive 
function in immune suppressed animals by reenabling the organism to 
react adequately to a secondary infection (22).   
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1.1.2.2 Rheumatoid Arthritis 
MIF is closely associated with the development of rheumatoid arthritis 
(RA) (16). RA is the most common inflammatory disease of the joints, it is 
estimated that 1% of adults in the U.S. and Europe suffer from RA. Key 
pathologic characteristics of RA are a marked expansion of the synovium 
by infiltrating leukocytes, the activation of  apoptosis of resident cells, and 
the participation of cytokines such as TNF-α and IL-1β. MIF is a key 
regulator for the migration of leukocytes into the joint in RA (23).  
In 1997, the role of MIF in inflammatory arthritis was reported for the 
first time (24). In a experimental model of collagen type-II induced 
arthritis the treatment with neutralizing anti-MIF antibodies before 
immunization with collagen led to a delayed onset of RA, lowered the 
frequency of arthritis, and reduced the levels of IgG2a. Treatment with 
neutralizing anti-MIF antibody also showed protective effects in the model 
of adjuvant-induced arthritis and antigen-induced arthritis (25, 26). 
Recent studies employing mif-/- mice confirmed the importance of MIF in 
arthritis. The severity of the disease, both in collagen-induced arthritis 
and antigen-induced arthritis, was less pronounced in mice with a deletion 
of the mif  gene (27, 28). It was shown that both Th1 and Th2 cells 
expressed high quantities of MIF, and that MIF stimulates the expression 
of MMP (matrix metalloproteinase) in FLS (29).  
In RA patients, MIF has been detected in synovial fluid, macrophages, 
endothelial cells, fibroblast-like synoviocytes (FLS), and CD3+ synovial 
lymphoid aggregates (30, 31), and MIF production is associated with 
disease activity.  
 
1.1.2.3 Atherosclerosis 
Atherosclerosis is characterized by the growth of atherosclerotic plaques in 
the vascular wall over the period of many years, leading to hardening and 
constriction of arteries. Inflammation and accumulation of large numbers 
of white blood cells (monocyte-derived macrophages, macrophage-derived 
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foam cells, to a lesser degree Th1 cells) is now regarded as a crucial force in 
the initiation and progression of atherosclerotic lesion formation (32). Both 
cytokines (TNF-α, GM-CSF, IL-12) and chemokines (CXCL8, MCP1) are 
pivotal for the recruitment of monocytes and the activation of intimal 
macrophages/foam cells.  
Recent studies indicate an important role for MIF in atherogenesis, 
atheroma formation and vascular disease. In 2002, the strong 
overexpression of MIF in human atheroma lesions was reported for the 
first time. It was also reported that the increased expression of MIF is 
accompanied by an increase in disease progression. MIF protein was 
upregulated in HUVEC cells when the cells were incubated with oxidized 
LDL. Furthermore, stimulation of macrophages with oxidized LDL led to 
an enhanced secretion of MIF (33). Importantly, through interaction with 
the chemokine receptors CXCR2 and CXCR4, MIF is instrumental in 
inflammatory leukocyte recruitment in atherosclerosis, targeting 
monocytes and neutrophils through CXCR2 and T cells through CXCR4 
(11). MIF is also causally linked to the development of atherosclerosis 
lesions. Mice lacking the low-density lipoprotein receptor (ldlr) are prone 
to develop atheroma. In comparison, mice lacking both ldlr and mif exhibit 
a reduction in atheroma lesions (34). Furthermore, it was reported that 
the neutralization of MIF in apoE-/- (apolipoprotein E) mice results in a 
marked reduction in inflammatory responses associated with 
atherosclerosis (35). It is also proposed that MIF serves as a link between 
rheumatoid arthritis and atherosclerosis (36).  
 
1.1.2.4 Asthma 
Asthma is a chronic, inflammatory disease of the respiratory system. In 
response to allergens such as tobacco smoke or air pollution, the airways 
constrict, become inflamed and produce excessive amounts of mucus.  
Studies in both mice and humans have supported a role of T helper 2 (Th2) 
cells in asthma which mediate allergic inflammation by producing 
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cytokines leading to the production of IgE, and the differentiation, 
proliferation and activation of eosinophils (37).  
Rossi and colleagues showed that human eosinophils stimulated with C5a 
or IL-5 release high amounts of MIF in vitro. Furthermore the 
bronchoalveolar lavage fluid obtained from asthmatic patients contains 
significantly elevated levels of MIF as compared to nonatopic normal 
volunteers (38). In 2005, genetic studies observing the prevalence of 
different MIF polymorphisms in asthma patients were performed. The 
MIF gene has a functional promoter polymorphism consisting of a 
tetranucleotide sequence, CATT, which is repeated five to eight times. A 
high number of repeats results in an increase in MIF promoter activity 
(39). While there was no association between particular alleles and 
asthma incidence, a significant association between a mild form of asthma 
and low-expression, 5-CATT MIF allele, was observed. Furthermore the 
study demonstrated that mif-deficient mice show less pulmonary 
inflammation and lower airway hyperresponsiveness than wildtype mice. 
This was in accord with the finding that mif-/- mice have lower titers of 
IgE and TH2 cytokines (13).  
 
 
1.1.3 Molecular Mechanisms of MIF Action 
1.1.3.1 ERK 1/2 Activation 
Different stimuli lead either to a transient (rapid, within minutes) or 
sustained (prolonged, for hours) activation of extracellular signal-
regulated (ERK) mitogen-activated protein kinases. MIF promotes both 
the transient and the sustained ERK 1/2 signaling pathway (40, 41).  
The sustained phase of ERK activation was shown to occur through 
autocrine and paracrine stimulation and depends on protein kinase A (41, 
42). It has been established that the sustained ERK 1/2 activation is 
associated with an activation of cytosolic phospholipase A2, overriding of 
glucocorticoids and a promotion of cell proliferation.   
Introduction  –  7 
Lue et al demonstrated that the stimulation of fibroblasts with MIF leads 
rapidly to a transient activation of the ERK 1/2 signaling pathway. They 
also established that transient ERK phosphorylation by MIF is dependent 
on a Src-kinase and leads to the phosphorylation and activation of the 
transcription factor Elk. 
 
1.1.3.2 MIF Inhibits JAB1 Activity 
In a yeast two-hybrid screen JAB1 (c-JUN-activation domain-binding 
protein-1) was identified as an intracellular binding partner of MIF (43). 
JAB1, also known as CSN5 (subunit 5 of the COP9 signalosome), 
regulates the degradation of p27Kip1 and activation of JNK (c-JUN N-
terminal kinase) and is a co-activator of AP-1, a transcription factor 
implicated in cell growth, transformation and cell death. MIF antagonizes 
these effects via the inhibition of the JAB1-dependent AP-1 transcription.  
Furthermore, MIF stabilizes the cell cycle inhibitor p27Kip1 by inhibiting 
the JAB1-mediated degradation of p27Kip1. 
Recently, it was reported that JAB1 traps MIF inside cells in order to 
prevent MIF secretion. The depletion of JAB1 protein led to an increased 
secretion of MIF (44), whereas the overexpression of JAB1 led to an 
inhibition of sustained ERK activation (40). Although there is no evidence 
for an active participation of JAB1 in the secretory pathway of MIF, JAB1 
nevertheless seems to have the ability to block MIF secretion and its 
autocrine and paracrine functions.  
 
1.1.3.3 MIF in Apoptosis 
p53 has a central role in the regulation of the cell cycle. In a screen to 
identify proteins which by-pass p53-dependent cell cycle control, MIF was 
identified as a negative regulator of p53 activity (45). MIF sustains 
macrophage survival by suppressing activation-induced, p53-dependent 
apoptosis (46). Mitchell and colleagues reported that LPS-challenge in mif-
deficient mice results in decreased macrophage viability, decreased 
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proinflammatory function, and increased apoptosis when compared to 
wild-type macrophages. In 2008, it was reported that MIF and p53 
interact physically, and that cysteine-81 in MIF is of critical importance 
for the physical and functional interaction (47). It is important to note that 
in comparable studies a direct, physical interaction between MIF and p53 
could not be detected (personal communication, J. Bernhagen).  
 
1.1.3.4 MIF Upregulates TLR4 Expression 
MIF has been implicated in the host response to LPS challenge in 
numerous studies. Toll like receptor (TLR) 4 forms a receptor complex 
with LPS binding protein and CD14, with TLR4 being the essential 
signaling component when LPS is bound to the receptor complex. It was 
demonstrated that mif-/- macrophages have a reduced expression level of 
TLR4, but not of LBP or CD14. The downregulation of TLR4 in mif-
deficient mice leads to a hyporesponsiveness towards LPS resulting in a 
reduced production of TNF-α, IL-1β, IL-6 and IL-12. (48). 
 
1.1.3.5 MIF Receptors 
Cytokines bind to their cell surface receptors and trigger an intracellular 
signaling cascade. CD74 was discovered as the cell surface receptor of MIF 
in 2003 (10). Surface plasmon resonance experiments between MIF and 
soluble CD7473-232 revealed an equilibrium Kd of ~9 nM. Leng et al 
reported that the MIF-dependent phosphorylation of ERK 1/2, the 
production of prostaglandin E2 and cell proliferation requires the cell 
surface expression of CD74. CD74 does not possess any obvious signal 
transduction domains; therefore, the molecular mechanism of signaling 
remained unclear for some time. Recent data showed that MIF’s binding 
to CD74 leads to the phosphorylation of CD74 at the intracytoplasmic 
domain in a CD44-dependent manner (49). The co-receptor CD44 was 
demonstrated to be the missing link of MIF/CD74-mediated sustained 
ERK activation via Src-kinases. 
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In 2007, the chemokine receptors CXCR2 and CXCR4 were discovered as 
non-cognate receptors for MIF in MIF-mediated migratory and 
atherogenic functions (11). MIF competed with cognate ligands for CXCR2 
and CXCR4 binding, and directly binds to CXCR2 and CXCR4 with a Kd of 
1.4 and 20 nM, respectively. Monocyte arrest induced by MIF involved 
both CXCR2 and CD74. Furthermore, it was described that CD74 and 
CXCR2 co-localize, suggesting a MIF signaling pathway via a 
CD74/CXCR2 complex. 
 
 
1.1.4 Structure, Enzymatic Activities and Inhibitors 
1.1.4.1 Structure 
The MIF protein consists of 114 amino acids. In 1996, the structure of MIF 
was solved independently by crystallography (50, 51) and NMR (52). The 
secondary structure of the MIF monomer consists of two α-helices and six 
β-strands, four of these strands form a β-sheet (Fig. 1).  
The structural analysis by crystallography revealed MIF to be a trimer, 
stabilized by hydrogen bonds and a hydrophobic core. The three 
dimensional structure of MIF possesses a strong homology to D-dopa-
chrome tautomerase (DDT) and the bacterial enzymes 5-carbodymethyl-2-
hydroxymuconate isomerase (CHMI) and 4-oxalocrotonate tautomerase (4-
OT) (53). These proteins are members of the MIF/tautomerase super-
family.  
Although crystallographic analysis revealed MIF to be a trimer, other 
studies, such as NMR and size exclusion chromatography, support the 
idea that MIF forms a monomer or dimer (52, 54). The question of the 
physiological state of MIF is still not answered to satisfaction.  
 
Introduction  –  10 
 
Fig. 1: The three-dimensional structure of MIF. Left: Human MIF monomer. Right: 
Human MIF trimer. Structures are drawn from PDB entry 1MIF using PyMOL (55). 
 
 
1.1.4.2 Enzymatic Activities 
There are two catalytic activities reported for MIF: a thiol protein 
oxidoreductase (TPOR) and a tautomerase/isomerase reaction.  
The base of MIF’s TPOR activity is located between residues 57 and 60 of 
MIF in its so-called CXXC-motif. Although not reconcilable with the 
crystallographic analysis of the recombinant reduced MIF trimer, the 
cysteines are reported to form reversible, intramolecular disulfide bonds 
(56). The CXXC-motif lies within the JAB1 binding site (57), and is 
structurally sensitive as mutations especially at C60 result in dramatic 
changes in the folding of MIF. 
The second enzymatic activity of MIF is a tautomerase function which it 
shares with all members of the MIF/tautomerase superfamily (DDT, 
CHMI, 4-OT). Proline-1 is the catalytic base in all proteins, and is highly 
conserved. It is not only present in vertebrate MIF, but also in MIF 
orthologs found in parasites such as Plasmodium falciparum and 
Leishmania major (58). So far the physiological substrate for the 
tautomerase activity is not known, but non-physiological substrates have 
been identified: D-dopachrome and hydroxyphenylpyruvate (59, 60) (Fig. 
2).  
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Fig. 2: The tautomerase reaction of MIF.  A) MIF catalyzes D-Dopachrome to 5,6-
dihydroxyindole-2-carboxylic acid.  B) Keto-enol isomerization of both p-hydroxyphenyl-
pyruvate and phenylpyruvate 
 
 
1.1.4.3 Small Molecule Inhibitors 
The active site of MIF around proline-1 was reported to be of importance 
for the pro-inflammatory actions of MIF. Mutational analysis revealed 
proline-1 to be involved in the counter-regulation of glucocorticoids, 
neutrophil priming and the upregulation of metalloproteinase-1 and 3 in 
rheumatoid arthritis synovial fibroblast (61-63). Prototypic small molecule 
inhibitors of MIF have been described that bind to the protein’s amino-
terminal tautomerase region. Prominent inhibitors are N-acetyl-p-
benzoquinone imine (NAPQI), (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid methyl ester (ISO-1), and 4-iodo-6-phenylpyrimidine 
(4-IPP) (61, 64, 65) (Fig. 3).  
ISO-1 binds reversibly to MIF and does not only inhibit the tautomerase 
activity of MIF, but also inhibits MIF’s ability to counter-regulate 
glucocorticoids (61), and protects mice from endotoxic shock (20). NAPQI 
binds covalently to MIF and the modification of MIF with NAPQI results 
in an inhibition of its tautomerase activity, decreased cell binding ability 
and a decreased immunorecognition (64). The inhibitor 4-IPP was found 
via computational virtual screening and also binds covalently to the amino 
acid proline-1. In contrast to NAPQI, which only bound to one third of MIF 
molecules, almost all MIF molecules were modified by 4-IPP. This is 
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reflected in the IC50 determined by D-dopachrome tautomerase assay; ISO-
1 has an IC50 of ~50 µM, NAPQI of ~40 µM, and 4-IPP of ~5 µM. 
Functionally, 4-IPP was reported to inhibit MIF-dependent cell motility 
and growth in vitro (65).   
 
 
 
Fig. 3: Small molecule MIF inhibitors. Left: NAPQI, Middle: ISO-1, Right: 4-IPP 
 
 
1.1.5 The Structural Homolog D-Dopachrome Tautomerase 
D-dopachrome and p-hydroxyphenylpyruvate serve as substrate for the 
tautomerase activity of both MIF and D-dopachrome tautomerase (60, 66). 
But in contrast to MIF, which converts D-dopachrome to 5,6-
dihydroxyindole-2-carboxylic acid, DDT decarboxylases D-dopachrome to 
5,6-dihydroxyindole. The enzymatic activity of DDT was first described in 
melanocytes (67); higher activities later were reported in human liver and 
blood (68). 
Murine DDT protein shares only 28% identity and 45% homology with 
murine MIF.  Of note, proline-1, the catalytic base of the tautomerase 
activity in MIF is conserved in DDT. Furthermore, the active side residues 
lysine-32 and isoleucine-64 also are present in DDT (Fig. 4). Interestingly, 
DDT possesses no CXXC-motif which is associated with the TPOR activity 
in MIF (56).  
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Fig. 4: Sequence alignment of mouse MIF with mouse D-dopachrome 
tautomerase. The secondary structure of mouse MIF is shown (Pdb: 1MFI). Elements of 
the secondary structures are indicated by α for α-helix and β for a β-strand of β-sheet, η 
for a short α-helix and T for turns. The sequence identity of mouse DDT and mouse MIF 
is 28%. Invariant residues among DDT and MIF are marked by black background; if 
residues are similar they are marked by a box. 
  
 
Human DDT protein was crystallized in 1999. The overall folding and 
subunit topology are almost identical to human MIF, with two αβα motifs 
related by a pseudo 2-fold symmetry and similar trimeric β-sheet packing 
(Fig. 5) (69).  
 
 
Fig. 5: Human D-dopachrome tautomerase. Left: Human DDT monomer. Right: 
Human DDT trimer. Structures are drawn from PDB entry 1DPT with PyMOL (55). 
 
 
To date, little is known about the biological functions and mechanisms of 
action of DDT. It is highly expressed in the liver, and also found in 
kidneys, brain, spleen, lung and the heart (70). In 2003, it was reported 
that DDT activity is increased in UVB-induced blister fluid. 
Correspondingly, the activity of MIF was also found to be increased (71). A 
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more recent study suggests a role for DDT in cancer. Coleman et al 
reported about the individual and cooperative action of MIF and DDT in 
angiogenesis showing that the depletion of MIF and/or DDT reduces the 
basal secretion level of CXCL8 and VEGF from non-small cell lung 
carcinoma cells. The transcriptional regulation of CXCL8 by MIF and DDT 
appears to involve JNK, c-JUN and AP-1. Furthermore, they showed that 
the MIF receptor CD74 is necessary both for MIF and DDT induced JNK 
activation (72).   
 
 
 
1.2 Classical Secretion in Eukaryotes 
Over the last two decades, considerable progress was achieved in 
improving the understanding of protein export. The process requires 
multiple components including the endoplasmatic reticulum (ER), the 
Golgi, and secretory vesicles.  
Proteins targeted for the conventional export into the extracellular milieu 
possess a signal peptide. This sequence directs the ribosome to the rough 
ER membrane and initiates the transport of the growing peptide chain 
across it into the lumen of the ER (73, 74).  
The ER is one of the largest intracellular compartments in cells and 
consists of a large network of membrane cisternae (75). Proteins are 
translated into the lumen of the ER, where they either fold into their 
native structure by themselves or with the aid of chaperones. The proteins 
are screened for their proper folding (76), before being transported to the 
Golgi in cargo vesicles (77). Misfolded proteins are degraded by the 26S 
proteasome (78). 
The Golgi, a highly dynamic organelle, is polarized with a cis-side facing 
the ER, and a trans-side, communicating with the plasma membrane. On 
their way through the Golgi, proteins are further processed mainly by 
“trimming” of N-glycosylations obtained in the ER (79). Over the trans-
Golgi network, cargo proteins exit the Golgi and are transported to the 
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plasma membrane in vesicles. Proteins are released into the extracellular 
space via a fusion of the carrier vesicles with the plasma membrane (80) 
(Fig. 6). 
 
 
Fig. 6: Secretory pathway. Proteins destined for export are transported in COPII-
coated vesicles from the ER to the cis-Golgi; they are leaving the Golgi at the trans-side 
and are transported in vesicles to the plasma membrane. Resident ER proteins are 
returned from the Golgi to the ER in COPI-coated vesicles.  
 
 
1.2.1 ER/Golgi Transport and the Golgi Apparatus 
1.2.1.1 ER to Golgi Transport  
Proteins leave the ER not uniformly across the ER, but at distinct exit 
sides, also called transitional ER (tER) sides. At these sites, no ribosomes 
are docked to the ER, and an increase in budding activity is evident by 
electron microscopy (81, 82). At the tER, COPII-coated vesicles bud off 
carrying cargo to the Golgi. 
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These vesicles uncoat and fuse to form tubular clusters, termed vesicular-
tubular clusters (VTCs) (83). VTCs become part of the cis-Golgi network, 
and ER-resident proteins are recycled in COPI-coated vesicles in 
retrograde vesicle transport (84).  
The ability of transport vesicles to fuse and form tubes is conferred by 
tethering factors which ensure specific binding interaction and SNAREs 
(soluble NSF attachment receptor) which facilitate the fusion of 
membranes (85). Tethering proteins act like ropes between a vesicle and 
target membrane. In addition to multi-component tethers such as the 
exocyst, which facilitates the binding of vesicles to the plasma membrane 
(86) or conserved oligomeric Golgi complex which is of importance in the 
intra-Golgi transport (87), there are also filamentous tethering proteins 
such as p115.   
SNAREs are subdivided into v- and t-SNAREs referring to their presence 
on either vesicles or target membranes. When v- and t-SNAREs are 
pairing, they form a SNAREpin and fusion occurs.  
It was reported that the tethering protein p115 which shares some 
sequence homology with SNAREs, is required (at least in vitro) for the 
initial interaction of SNAREs (88). 
After cargo proteins reach the Golgi from the ER by tethering and fusion 
of their carrier vesicles, proteins traverse through the Golgi.  
 
1.2.1.2 The Golgi Apparatus 
Over the last 30 years, one of the most controversial discussions in protein 
export concerned the question how cargo proteins cross the Golgi and are 
modified by resident Golgi proteins.  
Two models are mainly discussed: On the one hand, there is the idea that 
cargo arrives at the cis-side of the Golgi and then traverse through the 
Golgi to the trans-side, the resident Golgi proteins stationary in their 
tubular structure. On the other hand, there is the hypothesis that as 
vesicles arrive from the ER, they form cis-tubular structures and then 
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progress to mature into trans-tubular structures. This implies that cargo 
proteins remain in their distinct structures and resident Golgi proteins are 
shuttled between the cisternae (89). In recent years, more and more 
evidence supports this second hypothesis of cisternal maturation. 
Recently, live imaging in yeast has provided direct evidence in support of 
this hypothesis (90, 91).  
 
 
1.2.2 The Tethering Protein p115 
The transport between ER and Golgi requires the tethering and fusion of 
vesicles. p115, belonging to the family of golgin proteins, is one of the best 
studied tethering proteins involved in this process (92).  
Golgins were originally identified as a group of proteins found in the sera 
of patients with a variety of autoimmune diseases (93). Members of the 
golgin family possess a coiled-coiled region forming a rod-like structure 
(94). Localization studies showed that p115 predominantly localizes to the 
cis-Golgi, and it was also detected on COPII-coated vesicles (95, 96).  
p115 has a globular head, a extended coiled-coiled (CC) region and a short 
acidic tail (Fig. 9). It forms a parallel homodimer by dimerization in the 
CC region (97). Distinct domains interact with different proteins: the 
acidic carboxy-terminal tail interacts with the golgin proteins GM130 (98) 
and giantin (95), the CC1 domain of p115, a region with SNARE homology,  
interacts with SNARE family members such as syntaxin 5 (88, 99), the 
guanosine triphosphatase Rab1 mediates the recruitment of p115 by 
interacting with the globular head (96).   
p115, located at the cis-Golgi, tethers COPI-coated vesicles due to its 
interaction with giantin and GM130. Furthermore, p115, located to 
COPII-coated vesicles, tethers these vesicles in a SNARE-dependent 
process to form VTCs. These VTCs then dock with the cis-Golgi facilitated 
by an interaction between p115 and GM130. All tethering functions of 
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p115 are mediated through the interaction of p115 with Rab1 (Fig. 7) 
(100).  
 
 
Fig. 7: Tethering functions of p115. A) COPII-coated vesicles are tethered by p115. 
Rab1 recruits p115 on these vesicles by interaction with the globular head. Tethered 
vesicles fuse in a SNARE-dependent manner and form VTCs.  B) Docking of VTCs to the 
cis-Golgi is facilitated by the interaction of p115 and GM130. The acidic carboxy-terminal 
tail of p115 binds to a basic amino-terminal region of GM130.  C) Role of p115 in the 
tethering of COPI-coated vesicles. Giantin, located on the COPI-coated vesicles interacts 
with GM130 and p115 on the cis-side of the Golgi. Figure taken from (100).   
 
 
In various studies it was demonstrated that p115 is essential for the 
integrity of the Golgi. Both a depletion of p115 below detectable levels and 
the injection of antibodies targeting p115 led to a fragmentation of the 
Golgi (92, 101-103). It was furthermore reported that the fragmentation of 
the Golgi by targeting p115 led to a decreased protein transport from the 
ER to the cell surface (92).  
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1.3 Non-Classical Secretion 
In contrast to the classical secretion of proteins where proteins are 
exported via the ER/Golgi route, the pathway of non-classical secretion is 
not uniform. Unconventionally secreted proteins do not possess a 
hydrophobic signal peptide and therefore are not translocated into the 
lumen of the ER. In contrast to classically secreted proteins, proteins 
lacking a signal peptide are translated on free ribosomes. Evidence for this 
heterogeneous group of proteins that is secreted from cells without 
entering the ER/Golgi pathway came from the observation that leaderless 
proteins are not inhibited in their secretion by brefeldin A (104-107). 
Brefeldin A is an anti-fungal drug that interferes with the anterograde 
protein transport from the ER to the Golgi, and causes a rapid 
fragmentation of the Golgi (108, 109). 
Distinct mechanisms were suggested to describe non-conventional protein 
secretion including vesicular transport via either lysosomes and exosomes, 
and vesicle-independent export via plasma membrane shedding and direct 
translocation mediated by transporters in the plasma membrane (Fig. 
8)(110).  
 
 
Fig. 8: Potential export routes of non-conventionally secreted proteins. 1: Export 
by secretory lysosomes; 2: Export mediated by plasma membrane-resident transporters; 
3: Export through the release of exosomes derived from multivesicular bodies; 4: Export 
mediated by plasma membrane shedding of microvesicles. Figure taken from (110). 
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1.3.1 Vesicle-Independent Translocation 
1.3.1.1 Membrane Blebbing/Exovesicles 
The plasma membrane is highly dynamic, and its reorganization is 
controlled by small Rho GTPases. Specific Rho GTPases destabilize the 
actin filaments resulting in the formation of rounded cell protrusions, 
called membrane blebs (111). There are multiple, distinct types of 
membrane blebs including necrotic and apoptotic blebs. 
The export of the Leishmania protein HASPB (hydrophilic acylated 
surface protein B) belongs to the group of unconventionally secreted 
proteins employing the process of membrane blebbing (112). HASPB is 
only produced in the infectious stages of the parasite life cycle, and is then 
synthesized on free ribosomes. The amino-terminus of the protein becomes 
both myristolylated and palmitoylated which are necessary modifications 
for a membrane anchorage of the protein (113). Denny et al observed that 
myristylation and palmitoylation of HASPB at its amino-terminal SH-4 
domain leads to its redistribution to the plasma membrane. Both the 
deletion of the complete amino-terminus and the mutation of the 
myristylation site led to a redistribution of HASPB in the cytoplasm. 
Mutation of the palmitoylation site led to an accumulation of HASPB at 
the Golgi. In the secretion model proposed based on these observations, 
HASPB is first located to the Golgi and subsequently transported to the 
plasma membrane, probably using the conventional vesicular transport 
system. Once anchored to the plasma membrane, the SH4-domain of 
HASPB induces membrane blebbing in a Rho-dependent manner.  
 
1.3.1.2 Plasma Membrane-Resident Transporters 
Secretion facilitated by transporters residing in the plasma membrane is 
another possible way to export proteins independent of the ER/Golgi 
pathways. Fibroblast growth factors are heparan-binding growth factors 
that are activators of tumor-induced angiogenesis. Fibroblast growth 
factor (FGF) 2 is believed to be exported by direct translocation. 
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In an in vitro system employing inside-out vesicles it was demonstrated 
that FGF-2 is translocated across the plasma membrane and that the 
membrane-derived vesicles contain the molecular machinery necessary for 
an efficient export of FGF-2. The process is independent of ATP or a 
membrane potential; other proteins, among these MIF, were not able to 
translocate into the vesicles (114).  Before FGF-2 is able to translocate 
across the plasma membrane, it needs to be targeted to the plasma 
membrane. This likely occurs through the interaction with 
phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) (115). It was 
demonstrated that the downregulation of PI(4,5)P2 leads to a decreased 
export of FGF-2. So far, the actual transporter of FGF-2 in the plasma 
membrane has not been elucidated, but it is believed that heparan sulfate 
proteoglycans (HSPGs) probably serve as an extracellular trap to ensure 
the transport of FGF-2 into the extracellular space (116). 
        
                       
1.3.2 Vesicle-dependent secretion 
1.3.2.1 Lysosomal Secretion 
Secretory lysosomes share many features with conventional lysosomes. 
But in contrast to conventional lysosomes which are multi-vesicular in 
structure, secretory lysosomes have a more diverse structure. Both 
secretory and conventional lysosomes contain classical markers such as 
LAMP-1 and Hsc70, but secretory lysosomes additionally contain a specific 
cell-type specific set of components (117). 
Among the proteins reported to be secreted via lysosomes are interleukin-
1 (IL-1) β, heat shock protein (HSP) 70 and HMGB1 (118-120).  
Andrei et al demonstrated that IL-1β is co-fractioning with endolysosomes 
and that an inhibition of endolysosomal proteases leads to an increased 
IL-1β secretion. Via immunolocalization they revealed that IL-1β-positive 
vesicles also stain for the lysosomal marker LAMP-1 (118). Upon 
stimulation of cells, it is believed that these vesicles undergo fusion with 
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the plasma membrane and release IL-1β into the extracellular milieu 
(121). Similarly HSP70, a protein released from prostate carcinoma cells 
after heat shock, appears in the extracellular space at the same time that 
LAMP-1 appears on the cell surface, suggesting that lysosomes facilitate 
the unconventional secretion of HSP70.  
 
1.3.2.2 Exosomes/Multivesicular Bodies 
Exosomes represent another vesicle-based mechanism for export of 
proteins independent of the ER/Golgi pathway. Exosomes are a distinct set 
of membrane vesicles homogenous in form and size (122, 123). Exosomes 
were first identified as a mechanism for externalization of obsolete 
membrane proteins during reticulocyte maturation (124).  
The characterization of exosomes is based on morphology and biochemical 
criteria. The diameter of exosomes is between 50 and 90 nm, and they are 
released when multivesicular bodies (MBVs) fuse with the plasma 
membrane. Many cell types are known to release exosomes including 
hematopoietic cells, reticulocytes, B- and T-lymphocytes, dendritic cells 
and tumor cells (125).  
It was recently reported that the unconventional secretion of Cu, Zn 
superoxide dismutase (SOD1) is facilitated by exosomes (126). SOD1 was 
detected on isolated exosomes, but not on membrane blebs. In this study, 
the authors furthermore found p115 both on exosomes and membrane 
blebs.  
Another role for exosomes in the process of non-classical protein secretion 
is the export of the heat shock protein 90α (HSP90α) (127). In human 
keratinocytes, transforming growth factor α stimulates the rapid secretion 
of HSP90α via an exosomal secretion pathway. The inhibitor dimethyl 
amiloride inhibited the secretion of HSP90α in a concentration-dependent 
manner by blocking exosome-mediated protein secretion, while Brefeldin 
A did not show any inhibitory effects.  
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A further complication in the study of unconventional protein secretion 
comes from the fact that for some unconventionally secreted proteins 
several potential secretory pathways were described for one protein. 
Potential secretory pathways that have been described for interleukin-1 
(IL-1β) for instance, include cell surface blebbing and the formation of 
microvesicles that lyse in the extracellular space (128), and the fusion of 
endolysosomal vesicles with the cell surface plasma membrane (118). 
 
 
1.3.3 Role of ABC transporters in unconventional secretion 
The ATP binding cassette (ABC) transporter superfamily is one of the 
largest protein families known, with members in almost all organisms 
from bacteria to mammals and plants. These transmembrane proteins 
actively transport specific substrates across extra- and intracellular 
membranes. In eukaryotes, these proteins mainly transfer molecules to 
the outside of the cell. Classified in seven groups, 48 ABC transporter 
proteins are known in humans (129). Multiple drug resistance (MDR)-1 
was the first ABC transporter characterized in humans and it is also the 
best studied. MDR transporters are important in pharmacology, for 
example, they pump tumor suppressor drugs out of cancer cells (130).  
ABCA1 is a member of the subfamily ABCA and has been implicated as a 
regulator in cellular cholesterol and phospholipid homeostasis. 
Additionally, ABCA1 is reported to be involved in the unconventional 
secretion of several proteins; among these are IL-1β, HSP70, and Annexin-
1 (119, 131, 132). It was demonstrated that the pharmacological inhibitor 
of ABCA1, glyburide, inhibits the release of these proteins. In the case of 
Annexin-1 the results obtained by using pharmacological inhibition were 
confirmed in siRNA experiments targeting ABCA1. To date, no study was 
undertaken in regard to Annexin-1 and vesicles. However, it remains 
unclear whether ABC transporters are directly or indirectly involved in 
the unconventional secretion pathway of these proteins. 
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1.3.4 Unconventional Secretion of MIF 
As mentioned previously, MIF belongs to the heterogonous group of 
proteins that do not possess a signal peptide and are secreted by a 
specialized, unconventional pathway. MIF from bovine liver cell lysates or 
monocytes/macrophages does not become post-translationally N-
glycosylated although two potential N-glycosylation sites are present in 
the MIF cDNA sequence (6, 105).  Only after the experimental fusion of 
the leader-sequence of IL-2 to MIF, N-glycosylations of MIF were 
observed, indicating that native MIF is excluded from the classical 
secretory organelles ER and Golgi.  Furthermore, brefeldin A, an inhibitor 
of the ER/Golgi pathway did not affect the stimulated release of MIF from 
monocytes/macrophages and neutrophils, whereas glyburide and 
probenicide, inhibitors of the ABCA1 transporter, blocked the MIF 
secretion (105, 133). Of note, there is evidence that MIF is localized to 
vesicles in certain cell types (pituitary cells, β-cells of the pancreatic islets, 
and epididymal cells) (134-136). Interestingly, other unconventionally 
secreted proteins that are inhibited in their secretion by glyburide (IL-1β, 
HSP70) are also associated with vesicles.  
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2 Material and Methods 
2.1 Cell lines, Bacteria and Plasmids 
2.1.1 Cell lines 
Description  Cell type Morphology 
HeLa Human cervix carcinoma 
cells 
Epithelial, adherent 
HEK 293 Human embryonal kidney 
cells 
Epithelial, adherent 
RAW 264.7 Murine ascites leukemia 
cells 
Macrophage/monocyte, 
adherent 
THP-1 Human peripheral blood 
leukemia cells 
Monocyte, suspension 
 
2.1.2 Bacteria 
Strain Genotype Origin 
E. coli  
DH5α 
F- mcrA Δ(mrr-hsdRMS-mcrBC)φ80lacZ 
ΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 
7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen, 
Carlsbad, CA 
E. coli  
BL21 (DE3) 
F- ompT hsdSB (rB-mB-) gal dcm rne131 
(DE3) 
Invitorgen, 
Carlsbad, CA 
 
2.1.3 Plasmids 
Plasmid Insert Resistance/ 
Promotor  
Origin 
pET22b p115 Amp/ T7 this work 
pET22b DDT Amp/ T7 this work 
pET11b MIF Amp/ T7 Bucala +  
Bernhagen 
lab  
pENTR/U6 shRNA targeting p115 or 
lacZ  
Kan/U6 this work 
pAd/Block-iT 
Dest 
shRNA targeting p115 or 
lacZ 
Amp/U6 this work 
pAd/CMV/V5-
DEST 
p115 Amp/CMV this work 
pAd/CMV/V5-
DEST 
lacZ Amp/CMV this work  
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2.2 Equipment, Consumables and Chemicals 
2.2.1 Equipment 
Equipment Manufacturer 
Äkta FPLC system GE Healthcare, Piscataway, NJ 
Amaxa nucleofector Amaxa, Gaithersburg, MD 
Amaxa nucleofector Amaxa, Cologne, Germany 
Analytical balance Acculab, Columbia, MD  
Beckman Alegra6 centrifuge Beckman, Fullerton, CA 
Centrifuge 5417 R Eppendorf Eppendorf, Westbury, NY 
Centrifuge 5417 R Eppendorf Eppendorf, Wesseling-Berzdorf, 
Germany 
CO2 incubator Heracell Thermo Scientific, Waltham, MA 
CO2 incubator Heracell Heraeus Instruments, Hanau, 
Germany 
Electrophoresis Power Supply BioRad, Hercules, CA 
Heat block thermo mixer comfort Eppendorf, Westbury, NY 
HERA-Safe sterile bench Heraeus Instruments, Hanau, 
Germany 
HERA-Safe sterile bench Thermo Scientific, Waltham, MA 
iCycler BioRad, Hercules, CA 
HiTrap chelating HP column GE Healthcare, Piscataway, NJ 
Light microscope Carl Zeiss, Thornwood, NY 
Light microscope Olympus CK40 Olympus Co GmbH, Hamburg, 
Germany 
LSM510 confocal microscope  Carl Zeiss, Thornwood, NY 
NuPAGE/XCell II Blot Module Invitrogen, Carlsbad, CA 
NuPAGE/XCell SureLock Invitrogen, Carlsbad, CA 
ND-1000 Spectrophotometer NanoDrop, Wilmington, DE 
PTC-100 PCR BioRad, Hercules, CA 
Q Sepharose Anion exchange 
chromatography column 
GE Healthcare, Piscataway, NJ 
Superdex 75 size exclusion column GE Healthcare, Piscataway, NJ 
Sorvall Centrifuge Thermo Scientific, Waltham, MA 
SpectraMax Plus Molecular Devices, Sunnyvale, CA 
 
 
2.2.2 Consumables 
Consumables Manufacturer 
BioMax MS Film Kodak, Rochester, NY 
BioMax MR Film Kodak, Rochester, NY 
Blotting paper Whatman, Clifton, NJ 
C8 Sep-Pak  Waters, Milford, MA 
Cell culture equipment BD Falcon, Bedford, MA 
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Cell culture equipment Greiner, Frickenhausen, Germany 
Centricon  Amicon Bioseparations 
Culture Slides BD Falcon, Bedford, MA 
Eppendorf tubes  Eppendorf, Westbury, NY 
Eppendorf tubes  Eppendorf GmbH, Wesseling-
Berzdorf, Germany 
ImmunoModule ELISA plate  Nunc, Rochester, NY 
ImmunoModule ELISA plate  Nunc, Roskilde, Germany 
NuPAGE 4-12% Bis-Tris-Gels Invitrogen, Carlsbad, CA 
Polypropylene tubes BD Falcon, Bedford, MA 
PVDF membrane  Millipore, Bedford, MS 
Thin wall PCR tubes BioRad, Hercules, CA 
 
 
2.2.3 Chemicals 
Chemicals Manufacturer 
Acetonitrile J.T.Baker, Phillipsburg, NJ 
Agarose Sigma, St. Louis, MO 
Ampicillin  Sigma, St. Louis, MO 
Bacto Agar  BD, Franklin Lakes, NJ 
BSA American Bioanalytical, Natick, MA 
Bradford Reagent BioRad, Hercules, CA 
Dimethylsulfoxide Sigma, St. Louis, MO 
DMEM Invitrogen, Carlsbad, CA 
DMEM Invitrogen, Eggenstein, Germany 
DNA ladder Invitrogen, Carlsbad, CA 
Dry milk powder BioRad, Hercules, CA 
DTT Sigma, St. Louis, MO 
EDTA American Bioanalytical, Natick, MA 
FBS Invitrogen, Carlsbad, CA 
FBS Invitrogen, Eggenstein, Germany 
Formaldehyde American Bioanalytical, Natick, MA 
Glycerol Sigma, St. Louis, MO 
Goat serum Sigma, St. Louis, MO 
human Serum  Cambrex, Walkersville, MD 
Imidazole Sigma, St. Louis, MO 
iQ Sybr Green BioRad, Hercules, CA 
Kanamycin Sigma, St. Louis, MO 
Lipofectamine 2000 Invitrogen, Carlsbad, CA 
Lipofectamine 2000 Invitrogen, Eggenstein, Germany 
Lipopolysaccharide 0111:B4 Sigma, St. Louis, MO 
Lipopolysaccharide 0111:B4 Sigma, Munich, Germany 
Luria Broth medium Invitrogen, Carlsbad, CA 
Na3VO4 Sigma, St. Louis, MO 
NaCl J.T.Baker, Phillipsburg, NJ 
NaF Sigma, St. Louis, MO 
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β-Mercaptoethanol Sigma, St. Louis, MO 
Methanol Fisher scientific, Pittsburgh, PA 
Nonidet P-40 Roche, Indianapolis, IN 
NuPAGE LDS sample buffer Invitrogen, Carlsbad, CA 
NuPAGE SDS running buffer  Invitrogen, Carlsbad, CA 
NuPAGE transfer buffer Invitrogen, Carlsbad, CA 
Phosphate buffered saline Invitrogen, Carlsbad, CA 
Penicillin/Streptomycin  Invitrogen, Carlsbad, CA 
PIC Complete Roche, Indianapolis, IN 
Protein Free Blocking buffer Thermo Scientific, Waltham, MA 
Protein G Sepharose  Sigma, St. Louis, MO 
RPMI 1640  Invitrogen, Carlsbad, CA 
RPMI 1640  Invitrogen, Eggenstein, Germany 
RT² SYBR Green SuperArray, Frederick, MD 
SeaBlue 2Plus Invitrogen, Carlsbad, CA 
SOC medium Invitrogen, Carlsbad, CA 
Sodiumdodecylsulfate Sigma, St. Louis, MO 
Superblock Pierce, Rockford, IL 
Streptavidin-HRP Promega, Madison, WI 
Stripping buffer Thermo Scientific, Waltham, MA 
TAE buffer Invitrogen, Carlsbad, CA 
TMB substrate system Dako, Carpinteria, CA 
Tris American Bioanalytical, Natick, MA 
Triton-X-100 Sigma, St. Louis, MO 
Trypsin/EDTA Invitrogen, Carlsbad, CA 
Tween-20 Sigma, St. Louis, MO 
 
 
2.2.4 Multi-Component Systems 
Kits Manufacturer 
AccuScript cDNA synthesis  Stratagene, La Jolla, CA 
Biotin protein labeling Roche, Indianapolis, IN 
ELISA (TNF-α, IL-1β, IL-6) ebioscience, San Diego, CA 
EZ-Link NHS-SS-Biotin Pierce, Rockford, IL 
GeneClean Qbiogene, Carlsbad California 
QIAprep MiniPrep Qiagen, Valencia, CA 
QIAprep MiniPrep Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Valencia, CA 
Qiashredder Qiagen, Valencia, CA 
SlowFade Antifade Invitrogen, Carlsbad, CA 
Super Signal West Dura (ECL) Pierce, Rockford, IL 
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2.3 Primary and Secondary Antibodies 
2.3.1 Primary Antibodies 
Antigen      Application* Species/Type** Manufacturer 
ß-Actin WB Mouse/M Sigma, St. Louis, MO 
Ct-LPS FACS Mouse/M DAKO, Carpinteria, CA 
DDT WB/ELISA Rabbit/P this work 
GAPDH WB Goat/P Santa Cruz 
Biotechnology, Santa 
Cruz, CA 
MIF (3H2F) ELISA Mouse/M Bucala lab 
MIF (XIV14.3) ELISA Mouse/M Bucala lab 
MIF (N20) WB/ELISA Goat/P Santa Cruz 
Biotechnology, Santa 
Cruz, CA 
MIF (IIID9) IFA Mouse/M Bucala lab 
MIF 
(MAB289) 
ELISA Mouse/M R&D Systems GmbH, 
Wiesbaden, Germany 
p115 WB/IFA Rabbit/P Calbiochem, San Diego, 
CA 
*WB: Western blot, IP: immunoprecipitation, IFA: Immunofluorescent assay, FACS: fluorescent –
activated cell sorting, ELISA: Enzyme-Linked Immunosorbent Assay 
**P: IgG polyclonal, M: monoclonal (IgG1) 
 
 
2.3.2 Secondary Antibodies 
Description Application* Species Manufacturer 
Anti-goat HRP WB/ELISA Donkey  Santa Cruz Biotechnology, 
Santa Cruz, CA 
Anti-mouse HRP WB Horse Cell signaling, Danvers, MA 
Anti-mouse 
Biotin 
ELISA Goat R&D Systems GmbH, 
Wiesbaden, Germany 
Anti-mouse 
Alexa568 
IFA Rabbit Invitrogen, Carlsbad, CA 
Anti-rabbit HRP WB Goat Cell signaling, Danvers, MA 
Anti-rabbit 
Alexa488 
IFA Goat Invitrogen, Carlsbad, CA 
*WB: Western blot, IFA: Immunofluorescent assay, ELISA: Enzyme-Linked Immunosorbent Assay 
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2.4 RNAi-targeting Sequences 
Description  Sequence 
RNAi GM130 5'-ATGAGAACATGGAGATCACC-3' 
RNAi p115-2                   5'-GCAGCTGGATTCATCTAATAG-3' 
RNAi p115-1 5'-GCAGTTGGTCCAAGGCTTAT-3' 
RNAi lacZ provided by Invitrogen, Carlsbad, CA 
RNAi PIP-K Validated siRNA, Qiagen, Hilden, Germany 
 
 
2.5 Quantitative PCR Primers 
Description Sequence 
MIF-forward 5'-CGGACAGGGTCTACATCAA-3' 
MIF-reverse 5'-CTTAGGCGAAGGTGGAGTT-3' 
β-Actin-forward 5'-GGATGCAGAAGGAGATCACTG-3' 
β-Actin-reverse 5'-CGATCCACACGGAGTACTTG-3' 
 
For quantification of p115 mRNA levels, p115 and β-Actin primers were 
designed and synthesized from SuperArray.  
 
 
2.6 Media, Buffer and Solutions 
2.6.1 Media 
All media contained 1 U/ml penicillin/streptomycin 
 
Complete growth medium for HEK293, 
HeLa and RAW264.7 
Concentration, 
percent 
DMEM 90 
FBS 10 
 
 
Complete growth medium for THP-1   Concentration, 
percent 
RPMI 1640 90 
FBS 10 
 
 
Complete growth medium for primary human 
macrophages  
Concentration, 
percent 
RPMI 80 
human AB serum 20 
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Complete growth medium for bone marrow 
derived macrophages 
Concentration, 
percent 
DMEM 50 
FBS 20 
L929 supernatant 30 
 
 
2.6.2 Buffers and Solutions 
All buffers were prepared with distilled water, if not stated otherwise.  
2.6.2.1 General Buffers 
TBS, pH 7.4 Concentration 
Tris-HCl, pH 7.4 20 mM 
NaCl 150 mM 
 
 
TBS-T, pH 7.4 Concentration 
TBS (buffer) 
Tween-20 0.05% 
 
 
RIPA Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 150 mM 
EDTA 2 mM 
Nonident P-40 1% 
Sodium deoxycholate 0.5% 
SDS 0.1% 
Protease inhibitors complex 1x 
 
 
2.6.2.2 Flow Cytometry  
Staining buffer Concentration 
PBS (buffer) 
FBS 1% 
Sodium azide  0.1% 
 
Fixing buffer Concentration 
PBS (buffer) 
Formaldehyde 3.7% 
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2.6.2.3 Human MIF ELISA  
Washing buffer Concentration 
PBS (buffer) 
Tween-20 0.05% 
 
 
Blocking buffer Concentration 
PBS (buffer) 
Sucrose 1% 
BSA 1% 
 
 
Reaction buffer Concentration 
PBS (buffer) 
EDTA 1mM 
BSA 0.1% 
Tween-20 0.05% 
 
 
Primary antibody  Concentration 
PBS (buffer) 
Anti-MIF antibody clone 3H2F 10 µg/ml 
 
 
HRP-coupled secondary 
antibody 
Concentration 
Reaction buffer  (buffer) 
Peroxidase-conjugated anti-MIF 
antibody 
1x 
 
 
2.6.2.4 Murine MIF ELISA 
Washing and reaction buffer are the same as for human MIF ELISA. For 
blocking, Protein Free T20 Blocking buffer is used.  
 
Primary antibody  Concentration 
PBS (buffer) 
anti-MIF antibody clone XIV.14.3 15 µg/ml 
 
 
Secondary antibody  Concentration 
reaction buffer (buffer) 
Anti-MIF antibody N20 0.6 µg/ml 
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Tertiary antibody  Concentration 
reaction buffer (buffer) 
Anti-goat antibody HRP conjugated 2 µg/ml 
 
 
2.6.2.5 Murine DDT ELISA 
Washing and blocking buffer are the same as for human MIF ELISA.  
 
Primary antibody  Concentration 
PBS (buffer) 
Anti-DDT antibody  15 µg/ml 
 
 
Reaction buffer Concentration 
TBS (buffer) 
BSA 0.1% 
Tween-20 0.05% 
 
 
Secondary antibody  Concentration 
reaction buffer (buffer) 
anti-DDT antibody (biotinylated) 0.6 µg/ml 
 
 
Tertiary antibody  Concentration 
reaction buffer (buffer) 
Streptavidin-HRP conjugate 2 µg/ml 
 
 
2.6.2.6 Ni2+-Column Purification 
Binding buffer Concentration 
Tris-HCl, pH 8 50 mM 
NaCl 200 mM 
Glycerol 10%  
Imidazole 20 mM 
β-mercaptoethanol 10 mM 
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Elution buffer Concentration 
Tris-HCl, pH 8 50 mM 
NaCl 200 mM 
Glycerol 10% 
Imidazole 500 mM 
β-mercaptoethanol 10 mM 
 
 
2.6.2.7 MIF Purification  
Binding buffer Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 150 mM 
 
 
Elution buffer Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 2000 mM 
 
 
Denaturation buffer Concentration 
TBS (buffer) 
Urea 8 M 
 
 
Renaturation buffer  Concentration 
TBS (buffer) 
DTT 5 mM 
 
 
2.6.2.8 DDT Purification  
Binding buffer Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 50 mM 
Elution buffer Concentration 
Tris-HCl, pH 7.4 50 mM 
NaCl 1000 mM 
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2.6.2.9 SDS-PAGE and Western Blot  
Running buffer Concentration 
MES running buffer 20x (NuPAGE) 1x 
For separation of low molecular weight proteins  
 
 
Running buffer Concentration 
MOPS running buffer 20x 
(NuPAGE) 
1x 
For separation of high molecular weight proteins  
 
Transfer buffer Concentration 
Transfer buffer 20x (NuPAGE) 1x 
Methanol 10% 
 
 
Blocking buffer Concentration 
TBS-T (buffer) 
Dry milk powder 5% 
 
 
Washing buffer Concentration 
TBS-T (buffer) 
 
 
2.6.2.10 Coomassie Staining 
Staining solution Concentration 
Coomassie Brilliant Blue R-250 0.25% 
Methanol  40% 
Glacial acidic acid 10% 
 
 
Destaining solution Concentration 
Methanol  40% 
Glacial acidic acid 10% 
 
 
2.6.2.11 Immunofluorescent Staining 
Fixing solution Concentration 
PBS (buffer) 
Formaldehyde 3.7% 
Triton-X-100 0.1% 
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Blocking solution Concentration 
PBS (buffer) 
Goat serum 5% 
 
 
2.7 Molecular Biology Techniques 
2.7.1 Measurement of DNA/RNA Concentration 
The concentration and purity of DNA/RNA was assessed by photometric 
analysis. The absorption of the nucleotides was measured at OD260 and 
OD280. One OD260 equals 50 µg/ml DNA and 40 µg/ml RNA. The ratio 
between OD260 vs. OD280 assesses the purity of the sample with respect to 
protein contamination. A quotient of 1.8 to 2.0 indicates an 
uncontaminated sample.   
 
2.7.2 Polymerase Chain Reaction (PCR) 
DNA fragments were amplified using native Pfu DNA polymerase 
(Stratagene).  In contrast to the Taq polymerase, Pfu polymerase has a 
proofreading activity, resulting in fewer mutations in the process of 
amplification.  
The reaction mixture was prepared according to the manufacturer’s 
recommendations. The profile for amplification included:  
 
Step Number of cycles Temperature  Duration 
1 1 95 ºC 45 sec 
2 25 – 30 95 ºC 
Tm – 5 ºC 
72 ºC 
45 sec 
45 sec 
1 min per kb of PCR target 
3 1 72 ºC 10 min 
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2.7.3 Enzymatic DNA Digestion 
For the hydrolytic restriction of DNA, vector/insert DNA was incubated 
with the desired restrictionendonucleases according to the manufacturer’s 
instructions.     
 
2.7.4 Agarose Gel Electrophoresis 
In order to identify and/or purify DNA after PCR or DNA restriction, DNA 
was separated according to its mass in 1% agarose gels. The running 
buffer contained ethidium bromide for visualization of DNA under UV 
light.  
 
2.7.5 Isolation and Purification of DNA from Agarose Gels 
DNA from PCR reactions or restriction reactions were run on an agarose 
gel and the desired bands cut from the gel with a razor blade. DNA was 
eluted using GENECLEAN® III Kit according to their instructions.  
 
2.7.6 DNA Ligation 
For the ligation reactions, T4 DNA ligase was used. 50 – 100 ng vector 
DNA were incubated with the insert at a molar ratio of 1:3 in the 
recommended buffers with 5 U T4 Ligase at 4 ºC over night.  
 
2.7.7 Heat shock Transformation of E. coli  
After thawing an aliquot of competent cells on ice, bacteria were incubated 
with plasmid DNA for 30 min on ice prior to transformation. Heatshock 
transformation occurred via incubation for 30 sec at 42 ºC. Subsequently, 
bacteria were kept on ice for two minutes and then incubated at 37 ºC for 1 
h in SOC medium. Bacteria were then plated on LB-agar plates containing 
the appropriate antibiotics.   
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2.7.8 Plasmid Isolation 
Plasmids were isolated with the Plasmid Mini Kit from Qiagen according 
to the manufacturer’s recommendations.  
 
2.7.9 Isolation of RNA and cDNA Synthesis 
For the isolation of RNA the RNeasy kit was used according to the 
manufacturer’s instruction. RNA was converted to cDNA by reverse 
transcriptase. Oligo-dT primers were used for priming polyadenylated 
RNA. For an efficient cDNA synthesis, RNA together with the primers 
were denatured at 65 ºC for 5 min, followed by a 5 min cooling period at 
room temperature to allow the primers to anneal to the RNA. The 
synthesis reaction was carried out at 42 ºC for 1 h. After heat inactivation 
of the reverse transcriptase, cDNA was stored at –20 ºC. 
 
2.7.10 Quantitative PCR 
Quantitative PCR (qPCR) is a modification of the polymerase chain 
reaction, and is used to analyze gene expression. After the synthesis of 
cDNA, primers specifically amplify the gene of interest in the presence of 
SYBR green which only emits fluorescence after intercalating into double 
stranded DNA.  
The qPCR was performed on the iCycler from BioRad. The amplification 
profile included denaturation at 95 °C for 5 min, followed by one step 
annealing and elongation for 1 min at 60 °C for a total of 40 cycles. For 
verification of specific product amplification a melting curve was 
performed. 
 
2.7.11 Design and Production of short hairpin RNA  
The Block-it RNAi designer from Invitrogen was used to design short 
hairpin RNA molecules (shRNA) specific to human p115. Two constructs 
were designed: p115-1 from position 2625 to 2645 (5'-
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GCAGCTGGATTCATCTAATAG-3') and p115-2 from position 1601 to 1620 
(5'-GCAGTTGGTCCAAGGCTTAT-3') in the human p115 mRNA sequence 
(NM_003715). Both constructs share no significant sequence homology 
with other genes as analyzed by BLAST search. As negative control, 
shRNA constructs against lacZ (provided from Invitrogen) were generated. 
Oligonucleotides were cloned into the RNA expression vector pENTR/U6 
and confirmed by sequencing.  
 
2.7.12 Preparation of Adenoviruses 
shRNA constructs p115-2 and lacZ in the pENTR/U6 vector were 
recombined with the adenoviral vector pAd/BLOCK-iT-DEST using 
Gateway LR Clonase according to the manufacturer’s protocol. The 
resulting p115/pAd plasmid was transfected into HEK293 and amplified 
following the standard procedure described in the manual. The viral titer 
was determined using AdenoX Rapid Titer Kit (Clontech, Palo Alto, CA).  
 
 
2.8 Cell Culture Techniques 
2.8.1 Cultivation and Treatment  
All cell culture work was performed in BL2-approved laminar flow hoods. 
For cultivation, cells were kept in a humidified atmosphere at 37 ºC with 
5% CO2. All media and solution were sterile and endotoxin free. Adherent 
cells were passaged at a confluence of 70 – 80%. Cells were washed twice 
with PBS and then detached from culture flask using Trypsin/EDTA. Cells 
were re-plated in fresh medium at a confluence of 10%. Suspension cell 
were passaged every third day. 
For differentiation of THP-1 monocytes to macrophages, cells were treated 
with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) for 24 h. 
Subsequently, cells were cultured for additional 48 h (137).  
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For MIF secretion assays, cells were incubated in RPMI + l% FBS medium 
for 3 h prior to stimulation to quiescent cells. MIF secretion was 
stimulated with lipopolysaccharide (LPS). THP-1 monocytes and primary 
human macrophages were stimulated with 10 µg/ml LPS, PMA-
differentiated macrophages were stimulated with 0.1 µg/ml LPS.  
 
2.8.2 Isolation of Macrophages from Blood 
Human PBMCs were isolated by Ficoll-Hypaque gradient centrifugation. 
The cells were resuspended in RPMI 1640 medium supplemented with 
20% human AB serum and plated at 2.5x106 cells per well in 24-well cell 
culture plates. After 2 h of culture, the adherent cells were washed 
extensively with PBS and cultured for 1 week to allow differentiation into 
monocyte-derived macrophages (MDMs).   
 
2.8.3 Transient Transfection 
Depending on the cell type, different methods were employed for 
transfection. HeLa and HEK293 cells were transfected with Lipofectamine 
2000, a cationic, lipid-based transfection reagent. THP-1 monocytes were 
transfected by Amaxa electroporation utilizing program V-001 and the 
nucleofector solution V.  
Adenovirus-mediated transfection was performed to efficiently transfer 
plasmids into differentiated THP-1 macrophages and primary human 
macrophages. PMA-differentiated cells were incubated with a multiplicity 
of infection (MOI) of 50 over night; primary macrophages were incubated 
with 50 MOI of adenovirus for 2 h. 
Depending on the cell type, transfection method and construct, cells were 
cultured between 48 and 96 h after transfection.  
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2.8.4 Preparation of Cell Lysates 
The preparation of cell lysates for Western blot analysis included the 
following steps: washing of cells with ice cold PBS, lysis of cells by 
incubation in RIPA buffer containing protease and phosphatase inhibitors 
for 20 min at 4 ºC, removal of genomic DNA and cell debris by 
centrifugation for 10 min at 14,000 rpm at 4 ºC.   
 
2.8.5 Immunofluorescent staining for microscopy 
Cells were plated at a confluency of 80% on culture slides. For fixation and 
permeablization, cells were incubated with fixation solution for 20 min at 
37 ºC. Cells were thoroughly washed with PBS, and then incubated with 
blocking buffer for 30 min at RT. Cells were incubated with primary 
antibody over night at 4 ºC, washed three times with PBS and then 
incubated with secondary antibody for 1 h at RT. To reduce fading during 
microscopy, the cells were mounted with Antifade. Primary and secondary 
antibodies were diluted in blocking solution according to the 
recommendations of the manufacturer. 
 
2.8.6 Fluorescence-based Quantification of FGF Export   
HeLa cells were genetically modified to express FGF-2-GFP and FGF-4-
GFP fusion proteins in a doxycycline-dependent manner (138). To quantify 
the secretion of FGF fusion proteins, cells were transfected with 
knockdown constructs targeting either p115, PIP-K (115), or a control 
sequence. After 96 h, the expression of the fusion protein was induced by 
doxycycline for 24 h. Cells were prepared for flow cytometry to detect cell 
surface associated FGF-2-GFP and FGF-4-GFP, respectively. Primary 
antibodies were decorated with APC-conjugated secondary antibodies and 
GFP fluorescence (intracellular and cell surface) and APC fluorescence 
(cell surface) were determined employing FACSCalibur flow cytometer 
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(BD Bioscience). Untransduced HeLa cells were used to determine 
autofluorescence signals.  
 
2.8.7 Chlamydia trachomatis (L1) Infection  
THP-1 cells were infected with C. trachomatis at an MOI of 10 for 1 h at 
RT by slow rotation in RPMI medium. Cells were washed with medium 
and resuspended in RMPI containing 10% FBS without antibiotics and 
cultivated at 1x106 cells per ml in 12 well plates. The infection rate was 
analyzed by flow cytometry. For FACS analysis, cells were washed in 
staining buffer and then fixed in 3.7% formaldehyde in PBS for 20 min at 
RT. Subsequently cells were permeabilized with BD Perm/Wash by 
incubating for 20 min on ice. Cells were stained with mouse anti-Ct LPS 
FITC antibody. 
 
 
2.9 Proteinchemistry and Immunology Techniques 
2.9.1 Determination of Protein Concentration 
The measurement of protein concentration was performed according to 
Bradford (139). After diluting the Bradford reagent 1:5 in water, samples 
were diluted 1:100 in Bradford solution. After incubation for 5 min at RT, 
the absorbance was measured at 595 nm. The concentration of the 
samples was calculated by interpolation from a BSA standard curve. 
 
2.9.2 SDS-PAGE 
Proteins were separated according to their size in the NuPAGE system 
using Bis-Tris 4 – 12% polyacrylamide gradient gels. Samples were boiled 
for 5 min in LDS sample loading buffer and separated at 180 V in 
NuPAGE/XCell SureLock chambers. Depending on the size of the protein 
analyzed, either MES running buffer for small molecular weight proteins 
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(3 – 50 kd) or MOPS running buffer for large molecular weight proteins 
(50 – 200 kd) was used. 
 
2.9.3 Coomassie Staining  
Coomassie brilliant blue is a triphenylmethane dye binding to the basic 
amino acids of proteins. To stain proteins after a SDS/PAGE, the gel is 
incubated with the Coomassie staining solution for 30 min at RT. For 
visualization of proteins, the gel was washed with destaining solution 
until only the dye bound to the proteins remains. The destaining solution 
was changed repeatedly.  
 
2.9.4 Western Blot 
Proteins separated in a SDS-PAGE were transferred to a methanol-
activated PVDF membrane using the XCell II Blot Module. The unspecific 
binding sites on the membrane were blocked by incubating the membrane 
for 2 h at RT in blocking buffer. The primary antibody was diluted 1:1000 
or according the manufacturer’s recommendations in blocking buffer and 
the membrane was incubated with primary antibody solution either for 2 
h at RT or over night at 4 ºC. Before the incubation with the HRP-coupled 
secondary antibody, the membrane was washed 3 times. The secondary 
antibody was diluted in blocking solution at 1:5000 and incubated with the 
membrane for 1 h. After washing the membrane, proteins were visualized 
by detecting the chemiluminescence emitted after addition of the ECL 
substrate. If the membrane was re-probed, the membrane was incubated 
in stripping buffer for at least 30 min at RT. After a thorough washing the 
membrane, immunoblotting procedure was repeated. For densitometric 
analysis, the Scion Image program from NIH was used.  
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2.9.5 Sandwich ELISA 
2.9.5.1 Human MIF ELISA 
The human MIF ELISA is a one-step solid phase assay performed as 
described previously (13). The samples were mixed with anti-MIF 
antibody-HRP construct and added to an ELISA plate pre-coated with 
anti-MIF antibody 3H2F. During the incubation, the MIF antigen binds 
simultaneously to the capture antibody on one side and the HRP-coupled 
anti-MIF antibody on the other side. After incubation and washing to 
remove unbound enzyme, the amount of bound enzyme in each well was 
detected by adding the substrate TMB. The reaction was stopped by 
adding an acidic stop solution, and the resulting color read at 450 nm in a 
microtiter plate spectrophotometer. The concentration of MIF in the 
samples was calculated by interpolation from the MIF standard curve.  
 
2.9.5.2 Murine MIF ELISA 
MIF concentration was measured as described previously (21).  Briefly, 96-
well microtiter plates were coated with the anti-MIF monoclonal antibody, 
washed, and blocked. 50 µl aliquots of each sample were added to the plate 
and incubated overnight at 4 °C. The plate was washed and incubated 
with polyclonal anti-MIF antibody (N-20). This was followed by the 
addition of anti-goat IgG antibody conjugated to HRP, and the antibody 
complexes were quantified after the addition of the substrate TMB.  
 
2.9.5.3 Murine DDT ELISA 
96-well microtiter plates were coated with 15 µg/ml polyclonal anti-DDT 
antibody over night at 4 ºC. Subsequently the plate was washed and 
blocked with 1% BSA, 1% Sucrose in PBS for 2 h at RT. 50 µl aliquots of 
each sample were added to the plate and incubated for 2 h at RT. After 
washing, biotinylated anti-DDT antibody was added. This was followed by 
washing and the addition of a streptavidin-HRP conjugate, which was 
Material and Methods  –  45 
incubated for 1 h at RT.  The amount of bound enzyme in each well was 
detected by adding the substrate TMB. The DDT concentrations were 
calculated by extrapolation from a sigmoidal quadratic standard curve 
using mouse DDT. 
 
2.9.5.4 TNF-α, IL-1β and IL-6 ELISA   
To measure the concentration of TNF-α, IL-1β and IL-6 the commercially 
available ELISA kits from ebioscience were used according to the 
manufacturer’s instructions.  
 
2.9.6 Protein Purification 
2.9.6.1 Overexpression of Proteins 
The DNA sequence of the protein of interest was cloned into the bacterial 
expression vectors (pET from Novagen). After transforming the constructs 
into competent E. coli BL21 (DE3), cells were cultured over night. The 
following day, LB medium was inoculated with the over night culture to 
obtain an OD600 of 0.1. Bacteria were grown until an OD600 of 0.6, and the 
expression of the protein was induced by the addition of IPTG to a final 
concentration of 1 mM. The expression lasted for 4 h; afterwards the 
bacteria were pelleted by centrifugation for 10 min at 3,000 rpm at 4 ºC. 
The supernatant was discarded and pellets stored at –20 ºC.  
 
2.9.6.2 Purification of Histidine-tagged Proteins 
After overexpression of histidine-tagged p115 or DDT, bacteria were 
resuspended in binding buffer and lysed by French Press. The crude 
bacterial extract was purified using a HiTrap chelating HP column with a 
linear gradient of 20 – 400 mM imidazole in 50 mM Tris, pH 8.0 and 200 
mM NaCl. The peak fractions, as determined by SDS-PAGE, were 
subjected to gel filtration chromatography. Protein purity was verified by 
SDS-PAGE/Coomassie staining and Western blotting.   
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2.9.6.3 Purification of MIF 
MIF was purified as described previously (6). Briefly, after overexpression, 
pelleted bacterial were resuspended in 50 mM Tris-HC1 pH 7.5, 150 mM 
NaCl and lysed using a French Press. The lysates was sterile filtered and 
then subjected to a MonoQ anion exchange chromatography. The MIF 
containing fractions were applied to a C8-SepPak reverse phase column. 
Weakly bound material was eluted with 20% acetonitrile. MIF then was 
eluted with six column volumes of 60% acetonitrile, frozen at –80 ºC, and 
lyophilized. For renaturation, MIF was dissolved in 20 mM sodium 
phosphate buffer containing 8 M urea and 5 mM DTT and dialyzed 
against 20 mM sodium phosphate buffer containing 5 mM DTT, followed 
by 20 mM sodium phosphate buffer alone.  
 
2.9.6.4 Purification of DDT 
Native DDT was overexpressed in E. coli BL21 (DE3). The bacteria pellet 
was resuspended in 50 mM Tris-HCl, pH 7.4, 50 mM NaC1 and lysed 
using a French Press. The lysate was sterile-filtered and subjected to a Q 
Sepharose anion exchange chromatography. The column was equilibrated 
with Tris-buffered saline. DDT was eluted with a salt gradient (50 mM 
Tris-HCl, pH 7.4, 1 M NaC1) and 7.5 ml fractions were collected. The 
DDT-containing fractions were combined, concentrated and subjected to a 
Superdex 75 size exclusion chromatography. One fraction contained pure 
DDT protein. One liter of E. coli culture resulted in 10 mg DDT protein. 
The protein was stored at –20 ºC. LPS content of the purified protein was 
not analyzed.  
 
 
2.9.7 In vitro MIF/p115 Binding Studies  
96-well protein-absorbent plates were coated with 1 µM p115 per well. 
After coating over night, the plate was washed with TBS-T and blocked 
with Superblock. After pre-incubating MIF at concentrations ranging from 
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0 – 4 µM with 150 nM biotinylated MIF for 2 h, the samples were added to 
the plate and incubated over night at 4°C. For detection of bound 
biotinylated MIF, a streptavidin-alkaline phosphatase conjugate was 
added after washing the plate. Using p-nitrophenylphosphate as a 
substrate for the alkaline phosphatase, the amount of captured protein 
was measured at 405 nm. For a reverse set-up of the assay, 1 µM MIF was 
coated and 150 nM biotinylated p115 incubated with unlabeled p115 at 
concentrations from 0 – 4 µM. Values are plotted as percent absorbance at 
405 nm relative to wells containing biotinylated MIF or p115 alone.  
 
 
2.10  In vivo Mouse Experiments 
2.10.1 LPS Shock  
LPS shock experiments were performed with 6 – 8 week old female 
BALB/c mice.  
4-IPP was diluted in DMSO to a concentration of 1 M. For the 
administration of 4-IPP, the stock solution was diluted in corn oil to a final 
concentration of 10 mg/ml. 100 µl of 4-IPP or vehicle control was injected 
intraperitoneally 2 h prior to LPS injection. 17.5 mg/kg LPS (0111:B4) was 
intraperitoneally injected for survival experiments (5). When serum 
cytokines levels were monitored, shock was induced with 15 mg/kg LPS. 
 
2.10.1.1 Serum Collection 
Blood was collected from mice by cardiac puncture. The mice were 
anaesthetized with isoflurane.  After the mouse was under a deep surgical 
anesthesia, blood samples were taken from the heart by a thoracotomy 
through the diaphragm. Blood was withdrawn slowly to prevent the heart 
from collapsing.  
Blood samples were incubated at 37 ºC for 30 min and then at 4 ºC over 
night. The next day, samples were centrifuged for 10 min at 1,600 rpm, 
and serum supernatant was transferred to a fresh tube.  
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2.10.2 Isolation of Bone Marrow-Derived Macrophages 
Bone marrow-derived macrophages were isolated from C57BL/6 mice. To 
obtain the tibia and femur for isolation of bone marrow, mice were 
sacrificed and legs dissected. After the removal of tissue from the bone, 
bone marrow was expelled by a jet of medium from both ends of the bone. 
4x106 cells were plated per petri dish in 10 ml of conditioned medium. 
After 4 days of cultivation, the medium was exchanged and cells were 
cultured for at least another 24 h. For experiments the cells were scraped 
off and plated at a concentration of 0.5x106/ml.  
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3 Results 
3.1 p115 Mediates the Secretion of MIF 
3.1.1 p115 is a Novel Interaction Partner of MIF 
In a yeast two-hybrid screen in the laboratory of Prof. Bucala, p115 was 
identified as a novel interaction partner of MIF. The interaction was 
affirmed by co-immunoprecipitation in a mammalian cell system.  
For the yeast two-hybrid screen, MIF cDNA served as “bait” and a human 
pituitary cDNA library was the prey (5). After co-transformation of bait 
and prey plasmids into Saccharomyces cereviciae cdc25H, 90 colonies were 
identified in a primary screen, but secondary and tertiary screening ruled 
out 75. The remaining 15 colonies carried proteins binding specifically to 
MIF. By DNA sequencing, one of the positive clones contained the carboxy 
terminal 780 bases of p115. p115 is a large protein of 962 amino acids, and  
consists of a globular head, four conserved coiled-coiled (CC) domains and 
a short acidic tail (97) with MIF binding at the CC region and/or the acidic 
tail (Fig. 9).  
 
 
Fig. 9: Schematic structure of p115. Top: Full length p115 with its globular head 
(blue), four coiled-coiled domains (black), and an acidic tail (red).  Bottom: Carboxy-
terminus of p115 (residues 702-962) that interacts with MIF.   
 
The intracellular interaction between MIF and p115 was further 
investigated by co-immunoprecipitation in mammalian cells. In the 
prostate carcinoma cell line LNcap, an endogenous interaction between 
MIF and p115 was observed by Western blot analysis for p115 after 
immunoprecipitation with anti-MIF, but not an isotype control antibody 
(Fig. 10).  
 Results  –  50 
 
Fig. 10. Co-Immunoprecipitation of MIF and p115. Endogenous MIF/p115 
complexes were co-immunoprecipitated from LNCap cells using a monoclonal anti-MIF 
antibody. p115 was detected by Western blot using a polyclonal anti-p115 antibody. IB: 
immunoblot. 
 
 
3.1.2 The MIF/p115 Interaction is Direct and Specific 
The discovery of p115 as an intracellular interaction partner of MIF was a 
new information that was pursued in this thesis for further validation and 
to address the question whether p115 could be involved in the secretion of 
MIF.   
In order to biochemically confirm and further characterize the interaction 
between MIF and p115, the carboxy-terminal region of p115 identified in 
the yeast two-hybrid screen (p115702-962) was recombinantly produced and 
purified. The purity and specificity of the product was verified by SDS-
PAGE followed by Coomassie staining or Western blot analysis visualizing 
the p115702-962 protein with an anti-p115 antibody (Fig. 11).  
 
 
Fig. 11: Purified recombinant p115702-962. Purity and specificity revealed by SDS-
PAGE followed by Coomassie staining (left panel) and Western blot (right panel).   
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A specific interaction between MIF and p115 was observed in an in vitro 
competition binding assay employing recombinant, immobilized p115702-962 
and biotinylated MIF.  As shown in Fig. 12, increasing concentrations of 
MIF, but not the addition of equimolar amounts of control protein 
(lysozyme), inhibited the interaction of biotinylated MIF with p115.  
Protein-protein interaction was verified by performing the reverse assay, 
i.e. measuring the binding of biotinylated p115702-962 to immobilized MIF.  
 
 
Fig. 12: MIF binding to p115 demonstrated by a competitive binding assay.  Left 
panel: MIF binds to immobilized p115702-962 in a concentration-dependent manner.  Right 
panel: p115702-962 binds to immobilized MIF in a concentration-dependent manner.  
Lysozyme served as a negative control. Results are expressed as mean±S.D. of duplicate 
measurements and are representative for three independent experiments.   
 
3.1.3 MIF Release from Human Monocytes 
Although MIF does not possess a leader sequence, it is released from cells 
in both a regulated and a specific manner. Human THP-1 monocytes were 
stimulated with 10 µg/ml LPS and an increase in the concentration of MIF 
in the supernatant was observed (Fig. 13, A). MIF release was detectable 2 
h after stimulation and reached its plateau after 4 h.   
The observed increase in the supernatant content of MIF was not the 
result of cell death, as the cell viability was verified by lactate 
dehyrogenase (LDH) assay. Supernatants from both LPS-stimulated and 
solvent control treated cells showed 3 – 5 mU/ml LDH activity. In 
contrast, cells treated with 0.1% Triton-X-100, a detergent, showed 100 
mU/ml LDH activity.  
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The increase in MIF protein concentration in the supernatant after LPS 
stimulation was not accompanied by an increase in the level of MIF or 
p115 mRNA in the monitored period of 6 h (Fig. 13, B). These data 
indicate that the initial release of MIF from THP-1 monocytes occurs from 
pre-formed pools and does not require the transcription of MIF mRNA.  
The results are in accord with previous reports that were based on the 
immunostaining and in situ hybridization of murine tissues after LPS 
administration in vivo (19, 140).  
 
 
Fig. 13:  Cell stimulation increases MIF secretion without affecting MIF or p115 
mRNA levels. A) Time course of MIF secretion from LPS-stimulated, THP-1 monocytes.  
THP-1 cells (1×106/ml) were treated with LPS (10 µg/ml) or PBS (control) and 
supernatants were collected at the indicated time for measurement of MIF by specific 
ELISA. Results are expressed as mean±S.E. of duplicate measurements from two 
independent experiments (n=4). P values were calculated by unpaired Student’s t-test for 
all time points. *p<0.01 for stimulated vs. unstimulated cells.  B) MIF and p115 mRNA 
levels in LPS-stimulated THP-1 monocytes.  RNA was isolated at indicated time points 
and analyzed by quantitative PCR. Results are expressed as mean±S.E. of three 
independent experiments. 
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3.1.4 Macrophage Activation Leads to a Redistribution of 
MIF  
The cellular distribution of MIF in macrophages in response to LPS 
stimulation was studied. In unstimulated macrophages, MIF appears 
present throughout the cytoplasm and p115 is localized predominantly in 
the perinuclear area in a pattern that is consistent with the Golgi (Fig. 14, 
A), which is in agreement with prior reports (95, 98). Upon activation of 
primary macrophages with LPS, MIF redistributes from the cytoplasm to 
a plasma membrane-proximal area, and a portion of p115 now appears 
dispersed in the cytoplasm (Fig. 14, B).  
 
 
 Results  –  54 
 
Fig. 14: Immunolocalization of p115 and MIF in macrophages. A) Macrophages 
were plated on a four-chamber culture slide (2.5×105 cells/ chamber). The cells were 
cultivated overnight, fixed with formaldehyde, and permeabilized with Triton-X-100.  
MIF (red) and p115 (green) were visualized by immunostaining with specific antibodies 
(1:200).  Yellow indicates an overlapping signal after merging.  B) Macrophages were 
stimulated with LPS (10 µg/ml) or PBS (unstimulated) for 4 h, fixed with formaldehyde, 
and permeabilized with Triton-X-100.  MIF and p115 were visualized by immunostaining 
with specific antibodies.  Images are representative for n=40 cells.  Scale bar=10 µm.     
 
 
3.1.5 p115 is Required for MIF Release in Monocytes 
3.1.5.1 RNAi-Mediated Depletion of p115 
p115 plays an essential role in vesicle transfer from the endoplasmatic 
reticulum to the Golgi complex and in Golgi re-assembly after mitosis (92, 
141). MIF secretion is not inhibited by brefeldin A, a pharmacological 
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inhibitor of the Golgi-retrograde transport, MIF does not enter the Golgi, 
and it is not glycosylated (105). It was nevertheless of interest to examine 
whether p115 was necessary for the release of MIF in response to 
activating stimuli. RNA interference (RNAi) constructs were generated for 
the gene-specific silencing of p115 and their efficacy tested in human 
HeLa and THP-1 cells. As shown in Fig. 15, two RNAi constructs specific 
for p115 (p115-1, p115-2) reduced the concentration of p115 protein by 50 
– 70% in the two cell types tested.   
 
 
Fig. 15: RNAi-mediated depletion of p115. HeLa or THP-1 cells were transfected with 
RNAi constructs specific for p115 (p115-1, p115-2) or a control plasmid (mock) and 
analyzed for cellular p115 content by Western blotting 48 h after transfection.   
 
 
3.1.5.2 Depletion of p115 Inhibits the Release of MIF  
The objective was to address, whether a p115 knockdown reduces the 
amount of MIF produced by LPS-stimulated THP-1 monocytes. 
Transfection of the p115-1 or p115-2 RNAi sequences resulted in a 30 – 
40% decrease in MIF release in response to LPS, while basal levels of MIF 
production were unaffected (Fig. 16). Of note, the LPS-stimulated 
secretion of the two conventionally-secreted cytokines, TNF- and IL-6, 
which both bear hydrophobic signal peptides, was not affected by a 
reduction in p115 protein. These data point to a potential specificity of 
p115 in mediating MIF secretion, and also indicate that the cellular 
depletion of p115 by the RNAi approach used herein does not appreciably 
affect the functioning of the ER/Golgi pathway.  
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Fig. 16: p115 depletion inhibits MIF secretion. THP-1 monocytes (1x106/ml) were 
transfected with p115 RNAi or mock RNAi plasmids and stimulated with LPS for 4 h. 
Supernatants were collected and analyzed for MIF, TNF and IL-6 by specific ELISA. 
Results are expressed as the mean±S.E. of four independent experiments. Statistical 
significance was determined for each p115 RNAi construct against mock RNAi by 
unpaired Student’s t-test, *p<0.05, **p<0.01. 
 
 
GM130 is a protein known to interact with the carboxy-terminal acidic tail 
of p115 (95). With the purpose of studying the role of GM130 in MIF 
secretion, GM130 was depleted in THP-1 cells by siRNA. The depletion of 
GM130 protein in THP-1 cells had no effect on LPS-stimulated MIF 
release (Fig. 17).  
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Fig. 17: Depletion of GM130 does not affect MIF secretion.  A) THP-1 cells were 
transfected with GM130 RNAi or mock control. 96 h after transfection, cells were lysed 
and GM130 content analyzed by Western blot and densitometry. Results are expressed as 
mean values ±S.D. of three independent experiments. B) GM130-depleted or control 
THP-1 cells were stimulated with LPS for 4 h, supernatants were collected and assayed 
for MIF content. Results are expressed as mean values ±S.E. of one experiment measured 
in duplicates; results are representative for three independent experiments. 
 
 
3.1.6 FGF-2 and FGF-4 Export in p115-Depleted HeLa cells 
To gain a broader understanding of the role of p115 in unconventional 
protein secretion, the export of the two cytokines, FGF-2 and FGF-4, was 
studied. While both of these proteins are released from cells in response to 
tissue injury (142-144), FGF-4 is secreted conventionally whereas FGF-2 
is translocated directly across the plasma membrane (114).  
In collaboration with the group of Prof. Walter Nickel, using a previously 
established doxycycline-inducible expression system (138 113), both total 
and cell surface-associated FGF-2 and FGF-4 protein levels were 
measured. Cellular depletion of p115 did not inhibit the export of either 
FGF-2 or FGF-4, while the secretion of FGF-2 was inhibited by depletion 
of phosphatidylinositol kinase (PIP-K), as previously reported (115) (Fig. 
18). The finding that the release of both conventionally secreted cytokines 
(TNFa, IL-6 and FGF-4) and unconventionally secreted cytokines (FGF-4) 
is not affected by a depletion of p115 suggests a specific role for p115 in 
the stimulated export of MIF.  
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Fig. 18: FGF export does not depend on p115. HeLa cells were transfected with 
mock, p115-2 or PIP-K RNAi constructs, FGF-GFP fusion protein production was induced 
by doxycycline after 96 h. FGF-GFP fusion proteins were measured after an additional 24 
h as total or cell surface fluorescence. Data are shown relative to the background level of 
GFP. Results are expressed as mean±S.D. of three independent experiments.  
 
 
3.1.7 Role of p115 in MIF Secretion in Macrophages 
3.1.7.1 MIF and p115 are Co-Secreted in Activated Macrophages 
In order to determine whether p115 is also of importance for stimulated 
MIF release in macrophages, THP-1 monocytes were differentiated into 
macrophages. Human THP-1 monocytes acquire many of the 
characteristics of mature, primary macrophages upon differentiation with 
phorbol 12-myristate 13- acetate (PMA), such as an increase in the 
expression of the LPS co-receptor CD14 and the induction of cytokine 
expression (137). Differentiated THP-1 macrophages thus respond to low 
doses of LPS and show a plateau in the MIF secretion response at an LPS 
concentration of 0.1 µg/ml. In addition to a lower threshold dose for 
stimulating secretion, differentiated THP-1 also secrete ~5 fold more MIF 
protein than undifferentiated THP-1 cells (Fig. 19).  
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Fig. 19: Dose-dependent secretion of MIF from LPS-stimulated THP-1 
macrophages. Cells (1x106/ml) were stimulated with the indicated dose of LPS for 4 h 
and the supernatants assayed for MIF content by ELISA. Results are expressed as 
mean±S.D. of two experiments, each measured in duplicates (n=4).  
 
 
Of note, ELISA and Western blot analyses of LPS-stimulated THP-1 
macrophages show a coordinated increase in secreted MIF and p115, and a 
corresponding decrease in the cellular protein levels over the observed 
time period of 24 h (Fig. 20).  Moreover, the supernatants of unstimulated 
macrophages contain only a modest amount of MIF and p115, and no 
apparent reduction in the cellular MIF and p115 content is measurable. 
These results taken together suggest that MIF and p115 are co-secreted.   
 
 Results  –  60 
 
 
Fig. 20: Co-secretion of MIF and p115 from macrophages. A) Differentiated THP-1 
macrophages were stimulated with 0.1 µg/ml LPS or PBS (control) and the supernatants 
were collected at the indicated time points.  MIF concentration was measured by ELISA; 
p115 release was determined by immunoblotting and subsequent densitometric analysis.  
B) Cell lysates of THP-1 macrophages stimulated with LPS or control (PBS) were 
prepared at the indicated time points. Intracellular MIF concentration was measured by 
ELISA, and intracellular p115 level was determined by Western blot and densitometric 
analysis.  The ELISA results are expressed as mean values ±S.D. of two independent 
experiments measured in duplicate. Densitometric results are expressed as mean values 
±S.D. of at least two independent experiments.  Statistical significance was determined 
by Student’s t-test comparing LPS-stimulated vs. control time point, *p<0.05, **p<0.01.    
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Of note, the LPS stimulation of bone-marrow derived macrophages also 
led to the export of both MIF and p115 protein (Fig. 21), affirming the 
results obtained from THP-1 macrophages.  
 
 
Fig. 21: Co-Secretion of MIF and p115 in primary macrophages. Bone-marrow 
derived primary macrophages (0.5×106/ml) were stimulated with 1 µg/ml LPS or control 
(PBS) and the supernatants collected at the indicated time points. MIF concentration was 
measured by ELISA and p115 content was determined by immunoblotting.   
 
 
Further evidence that MIF and p115 are co-secreted came from the 
observation that glyburide, an pharmacological inhibitor known to inhibit 
the secretion of MIF (105, 133), also shows an inhibitory effect on the 
secretion of p115 (Fig. 22). 
 
 
Fig. 22: The ABC-transporter inhibitor glyburide inhibits the secretion of MIF 
and p115. THP-1 macrophages were pre-treated with glyburide (2.5 µM) or solvent 
control (DMSO) for 1 h. Subsequently, MIF secretion was stimulated with LPS, and 
supernatant were collected 4 h later. MIF concentration in supernatants was measured 
by ELISA, and p115 concentration by Western blot analysis. MIF-ELISA: n=3 
measurements, p<0.05.  
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3.1.7.2 Adenovirus-Mediated Depletion of p115  
In order to deliver p115 siRNA to differentiated THP-1 macrophages, an 
adenovirus construct was utilized. Adenoviruses do not infect monocytes 
because of their low expression levels of integrins 3 and 5, which 
mediate adenovirus uptake. Upon differentiation to macrophages, the 
expression level of the  integrins is up-regulated and adenoviruses 
interact with the cells (145). The transfection of adenovirus encoding p115 
siRNA, but not a control adenovirus led to a reduced intracellular p115 
protein level in THP-1 macrophages (Fig. 23, A).  
It has been reported that a depletion of p115 below detectable levels 
compromises the structure of the Golgi and causes its fragmentation (102, 
103). By immunofluorescent microscopy it was confirmed that the 
morphology of the Golgi was not affected by the RNAi approach used 
herein (Fig. 23, B). 
Adenovirus-mediated delivery of p115 siRNA was also a successful 
approach to reduce the p115 protein level in human peripheral blood 
monocyte-derived macrophages (Fig. 23, C). 
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Fig. 23: Depletion of p115 by adenovirus-encoded siRNA in macrophages.  A) 
Differentiated THP-1 macrophages (1x106/ml) were transfected with an MOI of 50 of 
adenovirus encoding siRNA against p115 or mock control siRNA. 96 h after transfection, 
the cells were lysed and the protein content analyzed by Western blot and densitometry. 
The results are expressed as mean values ±S.D. of three independent experiments.  B) 
THP-1 macrophages were differentiated on culture slides and p115 depleted by 
adenovirus transfection. 96 h after transfection, cells were fixed and permeabilized and 
stained for p115 (green) and the Golgi marker GM130 (red). Scale bar=10µm.  C) 
Adenovirus-mediated depletion of p115 reduces p115 protein level in primary human 
macrophages. Human peripheral blood monocyte-derived macrophages (1x106/ml) were 
transfected with 100 MOI of adenovirus carrying siRNA against p115 or mock control. 
The cells were analyzed 48 h later for p115 content by Western blot. Knockdown of p115 
was evaluated by densitometry. The results are expressed as mean values ±S.D. of three 
independent experiments. 
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3.1.7.3 p115 is Required for the Secretion of MIF in Macrophages 
After p115 was depleted in macrophages via adenoviruses carrying siRNA 
targeting p115, the release of cytokines was stimulated with LPS. MIF 
secretion in p115 depleted macrophages was reduced in response to LPS 
stimulation in comparison to control cells over the 24 h experimental 
period (Fig. 24, A). By contrast, the release of TNF-, IL-6 and IL-1 was 
not affected by adenovirus encoded p115 siRNA, confirming that partial 
p115 reduction does not interfere with the integrity of the Golgi 
apparatus, while having a specific role in the release of MIF. Adenovirus-
mediated delivery of p115 siRNA also reduced p115 protein production in 
human peripheral blood monocyte-derived macrophages (Fig. 23, C), and 
reduced MIF release after stimulation with LPS by almost 50% (Fig. 24, 
C).    
 
 Results  –  65 
 
Fig. 24: LPS-stimulated MIF secretion in macrophages.  A) Time course of LPS-
stimulated MIF secretion in control or p115 siRNA treated THP-1 macrophages. 
Supernatants were collected at the indicated time points and MIF content was measured 
by ELISA. Supernatants also were assayed for TNF-, IL-6 and IL-1 by ELISA. The 
results are expressed as mean values ±S.E. of triplicate measurements of two 
independent experiments (n=6). Statistical significance was determined by comparing the 
curves obtained in p115 knockdown vs. mock control by two-way ANOVA analysis. C) 
LPS-stimulated MIF secretion is reduced in p115 siRNA, but not in mock siRNA treated 
PBMCs. MIF secretion was stimulated with 10 µg/ml LPS for 4 h and the supernatants 
analyzed for MIF content by ELISA. The results are expressed as mean values ±S.D. of 
two independent experiments each measured in duplicates (n=4). Statistical significance 
was determined by an unpaired Student’s t-test, *p<0.001. 
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The inhibition of MIF secretion also appeared to be dose-dependent with 
respect to the level of p115 depletion (Fig. 25). When compared to controls, 
a ~50% depletion of p115 was associated with a ~20% inhibition of MIF 
release, while a ~75% depletion of p115 was associated with a ~40% 
inhibition of MIF release.   
 
 
Fig. 25: Dose-dependent effect of p115 depletion on MIF secretion.  Differentiated 
THP-1 macrophages were transfected with 50 MOI of adenovirus encoding siRNA against 
p115 or mock control siRNA.  48 h after transfection (50% depletion of p115 compared to 
mock treated cells) and 96 h after transfection (75% depletion of p115 compared to mock 
treated cells), the cells were stimulated for 4 h with 0.1 µg/ml LPS. The supernatants 
were analyzed for MIF release by ELISA, and data are shown relative to mock treated 
cells.  Results are representative for two independent experiments measured in 
duplicates.  Statistical significance was determined by Student’s t-test, *p<0.05, **p<0.01. 
 
 
 
In p115-depletion studies, it was shown that the efficient release of MIF 
from monocytes/macrophages in response to LPS depends on the presence 
of p115.  To determine whether an excess of p115 protein leads to an 
enhanced secretion of MIF, p115 was overexpressed in THP-1 
macrophages utilizing an adenovirus construct carrying a p115 expression 
construct. The overexpression of p115 was confirmed by Western blot, and 
the effect of p115 overexpression on LPS stimulated MIF secretion was 
evaluated by ELISA (Fig. 26). The overexpression of p115 had no effect on 
the LPS-stimulated release of MIF or the conventionally secreted cytokine 
TNF-.  
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Fig. 26: Effect of p115 overexpression on MIF secretion.  A) Differentiated THP-1 
macrophages (1x106/ml) were transfected with an MOI of 100 of adenovirus encoding a 
construct for overexpression of p115 or a mock control. 48 h after transfection, the cells 
were lysed and the protein content analyzed by Western blot.  B) LPS-stimulated MIF 
secretion was not affected by the overexpression of p115. MIF secretion was stimulated 
with 0.1 µg/ml LPS for 4 h in macrophages overexpressing p115 or control cells, and the 
supernatants were collected and assayed for MIF and TNF- content by specific ELISA. 
The results are expressed as mean values ±S.D. of two independent experiments each 
measured in duplicates (n=4). 
 
 
3.1.8 p115 Mediates the Release of MIF from Infected Cells  
Chlamydiae are gram-negative, obligate intracellular bacteria that infect 
and replicate within monocytes/macrophages (146, 147). Infection of 
cultured THP-1 cells with Chlamydia trachomatis induces the release of 
pro-inflammatory cytokines (148). As shown in Fig. 27 this inflammatory 
stimulus also leads to the release of MIF with a peak 48 h post infection. 
After establishing that p115 is a required protein for the LPS-stimulated 
release of MIF, it was of interest to study the effect of C. trachomatis 
infection on MIF production in differentiated THP-1 macrophages that 
had been pre-treated with adenovirus encoding either mock control or 
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p115 siRNA. The depletion of p115 protein had no effect on the infection or 
replication rate of C. trachomatis in macrophages, as measured by flow 
cytometry for C. trachomatis lipopolysaccharide (Fig. 27, B). In accord 
with the previous results using LPS stimulation, macrophages treated 
with p115 siRNA showed a significant decrease in MIF secretion after C. 
trachomatis infection (Fig. 27). By contrast, the secretion of TNF-, which 
peaks 8 h after infection, was unaffected by p115 depletion. These data 
indicate that cellular p115 plays an important role in mediating MIF 
secretion by macrophages in response to both a defined microbial ligand 
such as LPS, as well as life infection by an intracellular pathogen such as 
C. trachomatis. 
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Fig. 27: p115 knockdown inhibits MIF secretion in Chlamydia trachomatis 
infected human macrophages.  A) THP-1 cells (1x106/ml) were infected with 10 MOI 
of C. trachomatis. Supernatants were collected at the indicated time points and analyzed 
for MIF release by ELISA.  B) p115-depleted or mock control THP-1 macrophages were 
analyzed for C. trachomatis infection and replication by flow cytometry. 24 h post 
infection, cells were washed, permeabilized, and stained for C. trachomatis using an anti-
LPS antibody. The results are representative for at least three independent experiments. 
Statistical significance of infection of p115 depleted vs. mock treated cells was analyzed 
by unpaired Student’s t-test. Mock siRNA: 38±5%, p115 siRNA: 39±8%.  C) THP-1 
macrophages were transfected with 50 MOI of adenovirus encoding a p115 or control 
(mock) siRNA construct 96 h prior to infection with C. trachomatis. Supernatants were 
collected at the indicated time points and the levels of MIF and TNF- were analyzed by 
ELISA. Results are expressed as mean±S.E. of one experiment measured in triplicates. 
Data are representative of three independent experiments. Statistical significance was 
analyzed by unpaired Student’s t-test, *p<0.01.  
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3.1.9 Small Molecule Inhibitor Blocks MIF Secretion  
Due to the unique structure of MIF and its tautomerase activity, several 
prototypic small molecule inhibitors targeting MIF function have been 
designed (61, 64). These inhibitors (ISO-1 and NAPQI) bind to MIF’s 
amino-terminal proline thus inhibiting the tautomerase activity. Mitchell 
and colleagues recently described the suicide substrate, 4-iodo-6-
phenylpyrimidine (4-IPP), and showed by crystallography that 4-IPP 
covalently binds to the amino-terminus of MIF (65). 
 
 
3.1.9.1 Immunorecognition of 4-IPP-Modified MIF  
In a prior report by Senter et al. it was observed that the covalent 
modification of the amino-terminus of MIF alters its immunorecognition in 
a two-antibody sandwich ELISA. Indeed, MIF that had been incubated 
with 4-IPP showed increased immunorecognition by a MIF-specific 
monoclonal antibody (clone MAB289) when compared to native MIF.  By 
contrast, when analyzing the 4-IPP/MIF complex with a different anti-
MIF mAb (clone 3H2F), a diminished recognition compared to native MIF 
was observed (Fig. 28). 
 
 
Fig. 28: 4-IPP modifies the immunorecognition of MIF in a two antibody 
sandwich ELISA. Quantification of 4-IPP modified MIF (MIF-4-IPP) or unmodified MIF 
(MIF) by two distinct ELISAs.  A) MIF-4-IPP shows decreased immunorecognition by the 
monoclonal anti-MIF antibody 3H2F.  B) MIF-4-IPP displays enhanced detection by the 
monoclonal anti-MIF antibody MAB289.  
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By contrast, the immunodetection of MIF by Western blot, which detects 
denatured, linearized proteins, was not affected by 4-IPP modification 
(Fig. 29).    
 
 
Fig. 29: Immunorecognition of 4-IPP modified MIF by Western blot. MIF was 
incubated with either vehicle control (DMSO), 0.1x molar excess of 4-IPP, or 10x molar 
excess of 4-IPP over night. Samples were run on a SDS-PAGE and transferred to a PVDF 
membrane. Unmodified and 4-IPP modified MIF were quantified and detected by 
Coomassie staining, Ponceau S staining, and Western blot (polyclonal anti-MIF 
antibody).  
 
 
3.1.9.2 4-IPP Targets the MIF/p115 Interaction 
Small molecule MIF inhibitors are able to inhibit MIF functions. It was 
reported that ISO-1 effectively protects mice from LPS shock and West 
Nile virus infection (20, 149). In these models, ISO-1 exhibited similar 
protective properties as neutralizing anti-MIF antibody or genetic mif 
deletion (21, 149).  
To analyze whether the prototypic inhibitor 4-IPP inhibits the release of 
MIF after LPS stimulation in THP-1 macrophages, Western blot analysis 
was employed to quantify released MIF. Fig. 30, A shows that 4-IPP 
effectively blocked the release of both MIF and p115 after LPS stimulation 
in macrophages. Analysis of the cytosolic concentration of MIF  and p115 
in response to LPS treatment showed that the level of both proteins in the 
cytoplasm was decreased by ~50% after stimulation with LPS, while in 
macrophages pre-treated with 4-IPP the intracellular concentration of 
MIF and p115 remained unchanged.  
4-IPP also reduced the secretion of MIF from monocytes infected with 
Chlamydia trachomatis (Fig. 30, B).  
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Fig. 30: 4-IPP inhibits MIF release from macrophages.  A) THP-1 macrophages 
(1×106/ml) were pre-treated with 1 µM of 4-IPP for 1 h prior to stimulation with 0.1 µg/ml 
LPS, and MIF and p115 was measured in supernatants and cell lysates by Western 
blotting.  Western blots were quantified by densitometry relative to β-actin.  Mean±S.E. 
of at least two independent experiments are stated below the blots.  Statistical 
significance for the comparison of LPS + 4-IPP vs. LPS alone was analyzed by an 
unpaired Student’s t-test, *p<0.05. 4-IPP did not compromise cell viability, supernatants 
showed LDH activity of >5 mU/ml LDH.  B) THP-1 monocytes were infected with an MOI 
of 10 of C. trachomatis and treated after infection with 1 µM of 4-IPP or control over the 
time of infection. Supernatants were collected at the indicated time points and analyzed 
for MIF content by Western blot. Results are representative for three experiments.  
 
 
In contrast, 4-IPP did not affect the LPS-stimulated release of TNF-α or 
IL-1β (Fig. 31, A); this affirms that 4-IPP has no overall effect on the 
secretion mechanism of cells. Furthermore, the influence of the reversible 
MIF inhibitor ISO-1 on MIF release from stimulated THP-1 macrophages 
was investigated, but no effect was observed (Fig. 31, B).  
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Fig. 31: 4-IPP does not target release of other cytokines, ISO-1 does not 
influence MIF release.  A) Supernatants of LPS-stimulated THP-1 macrophages that 
had been treated with 4-IPP or control assayed for the release of TNF-α and IL-1β. The 
results are expressed as mean±S.D. of one experiment measured in duplicates. Data are 
representative for two independent experiments.  B) THP-1 macrophages pre-treated 
with ISO-1 were stimulated with 0.1 µg/ml LPS. MIF release at the indicated time points 
was analyzed by ELISA. The results are expressed as mean±S.D. of one experiment 
measured in duplicates. Data are representative for two independent experiments. 
 
 
The observation that 4-IPP alters the immunorecognition of MIF by anti-
MIF monoclonal antibodies (Fig. 28) suggests that 4-IPP may impart a 
significant conformational affect on MIF that may influence its binding to 
p115. To test this hypothesis, the impact of 4-IPP on the competitive 
binding of MIF to p115 was examined in vitro. As shown in Fig. 32, 4-IPP, 
but not the small molecule MIF inhibitors ISO-1 or NAPQI (61, 64), 
increase MIF binding to p115. The enhanced binding of MIF to p115 in the 
presence of 4-IPP thus may play a role in the inhibitory action of 4-IPP on 
MIF release from cells, perhaps by interfering with additional protein 
interactions necessary for secretion.  
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Fig. 32: 4-IPP enhances the binding of MIF to p115. Competitive binding to 
immobilized p115 of biotinylated MIF vs. increasing concentrations of MIF pre-incubated 
with the small molecule MIF inhibitors 4-IPP, NAPQI, ISO-1, or solvent control. Results 
are expressed as mean±S.E. of one experiment measured in duplicate. The data are 
representative of three independent experiments.   
 
 
3.1.9.3 Effect of 4-IPP in LPS-Shock Model 
The small molecular MIF inhibitor ISO-1 has a protective effect in the 
LPS-shock model (20). Therefore, it was examined, whether the prototypic 
inhibitor, 4-IPP, also protects mice from LPS shock. 4-IPP had no 
significant effect on the survival following LPS challenge (Fig. 33).  
 
 
 
Fig. 33: 4-IPP does not protect mice in a model of endotoxemia. Female BALB/c 
mice (6-8 weeks) were intraperitoneally injected with 1 mg 4-IPP or vehicle control 
(DMSO and corn oil). 2h later, LPS was injected (17.5 mg/kg). Mice were observed for 6 
days. Data points are from one experiment (N=10 mice per group, p=NS), representative 
for three independent experiments.  
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In addition to studying the effect of 4-IPP on the survival of mice in the 
LPS-shock model, it was of interest to analyze whether the administration 
of 4-IPP modulates the release of MIF and other pro-inflammatory 
cytokines. In contrast to the in vitro experiments, 4-IPP did not 
significantly inhibit the release of MIF into the serum, although a modest 
reduction of MIF levels was observed. Cytokines downstream of MIF 
(TNF-α, IL-6) were also not targeted in their release by 4-IPP in the 
examined model (Fig. 34).  
 
 
 
 
Fig. 34: 4-IPP does not affect the release of MIF after LPS injection. Female 
BALB/c mice (6-8 weeks) were intraperitoneally injected with 1 mg 4-IPP or vehicle 
control (DMSO and corn oil). 2h later, a sublethal dose of LPS was injected (15 mg/kg). At 
the indicated time points, serum was collected and assayed for cytokine content by 
ELISA. (N=5 mice per group per time point), the experiment was performed three times 
independently.  
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3.2 D-Dopachrome Tautomerase (DDT) 
Like MIF, D-dopachrome tautomerase (DDT), catalyzes enzymatic 
reactions of the non-physiological substrate D-dopachrome in its amino-
terminal tautomerase active site.  
Since the “rediscovery” of MIF in the early 90s, the knowledge about MIF 
grew steadily, but little is known about DDT. Crystallographic analysis of 
DDT revealed that although MIF and DDT share only limited sequence 
homology, the three-dimensional structures of the two proteins show 
remarkable similarity (69). The gene structure of MIF and DDT also show 
similarities: The two proteins are closely linked on chromosome 22 (in 
humans) or chromosome 10 (in mice), respectively; moreover, the two 
proteins have an identical exon structure (150). Nevertheless, studies 
addressing the biological functions of the structural homolog of MIF are 
limited (72), and the molecular action of DDT remains unknown.  
 
 
3.2.1 Purification of D-Dopachrome Tautomerase  
3.2.1.1 Purification of Histidine-tagged DDT 
In order to expedite the process of obtaining pure DDT protein, mouse 
DDT cDNA was cloned into the pET22b vector. The resulting fusion 
protein possesses a short carboxy-terminal histidine tag (6x His), and was 
overexpressed in E. coli BL21 (DE3). Utilizing the carboxy-terminal 
histidine tag, DDT was purified over a Ni2+ column. The purity of the 
protein was determined by SDS-PAGE and Coomassie staining (Fig. 35).      
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Fig. 35: Purification of Histidine-tagged mouse DDT. Purified recombinant mouse 
DDT revealed by SDS-PAGE followed by Coomassie staining.  
 
 
The purified protein was sent to Pocono Rabbit Farm & Laboratory 
(PRF&L) for the production of a polyclonal anti-DDT antibody. A rabbit 
was periodically injected with 100 µg of DDT protein in Complete Freund’s 
adjuvant in the popliteal lymph nodes, serum was collected after day 28, 
42 and 70.  
 
3.2.1.2 Purification of Native DDT Protein  
From the MIF protein it is known that the amino-terminus is of 
importance not only for the tautomerase activity, but also for various 
biological actions (ERK 1/2 activation, glucocorticoids overriding ability, 
CD74 receptor binding). Similarly, the carboxy-terminus was shown to be 
crucial for the trimer formation (51), thus it was of importance to purify 
recombinant, native DDT protein, to successfully perform characterization 
studies. 
Two stop codons were cloned after the DDT cDNA in pET22b to prevent 
the expression of the carboxy-terminal histidine-tag and obtain native 
DDT protein; the insertion was confirmed by DNA sequencing. After the 
overexpression in E. coli BL21 (DE3), DDT was sequentially purified 
utilizing anion exchange chromatography, followed by gel filtration. Fig. 
36 shows the purification steps performed for obtaining pure protein. 
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Fig. 36: Sequential purification of mouse D-Dopachrome tautomerase.  A) DDT 
was overexpressed in E. coli BL21 (DE3) and lysed by French press. The lysate was 
loaded on a Q-Sepharose anion exchange chromatography column and proteins were 
eluted over a salt gradient. The collected fractions were analyzed by SDS-PAGE and 
Coomassie staining.  B) Fractions 2 – 5 of the anionexchange chromatography were 
pooled and concentrated. The combined fractions were subjected to a size exclusion 
chromatography. The DDT-containing fractions were collected and protein content and 
purity was determined by SDS-PAGE and Coomassie staining.  C) SDS-PAGE and 
Coomassie staining of fraction 8 of the gel filtration.  
 
 
The identity of the purified protein was confirmed by mass spectroscopy 
(Fig. 37). Mass spectroscopy showed two peaks: one at 12.947 kd, and one 
at 13.079 kd. The peaks correspond to the calculated molecular weight of 
DDT: 12.946 kd, when the amino-terminal methionine is post-
translationally cleaved off, 13.077 kd, when DDT still possesses the 
amino-terminal methionine.  
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Fig. 37: Mass spectroscopy of D-Dopachrome tautomerase. Electrospray ionization 
mass spectrometry of murine DDT showing a molecular mass (m/z) that lies within 
0.02% accuracy of the predicted m/z (13.077 kd and 12.946 kd). 
 
 
3.2.2 Establishment of a DDT-ELISA 
MIF and DDT share 28% sequence identity and the overall topology and 
trimeric formations of DDT are similar to those of MIF. Therefore, the 
newly produced polyclonal anti-DDT antibody was analyzed for cross 
reactivity with both human and murine MIF protein in Western Blot 
analysis. Fig. 38 demonstrates that the antibody detects DDT protein, 
while exhibiting no cross reactivity for murine or human MIF.  
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Fig. 38: Polyclonal anti-DDT antibody shows no cross reactivity for MIF in 
Western blot.   100, 10 and 1 ng protein (DDT, mMIF or hMIF) were separated on a 
SDS-PAGE gel and transferred on PVDF membrane. The membrane was probed with the 
IgG fraction of the serum obtained from PRF&L.  
 
 
In order to analyze and quantify, if DDT is released from cells, an indirect 
ELISA for DDT was established. The produced and purified anti-DDT 
antibody served both as a capture and detection antibody; the antibody 
was biotinylated when used as a detection antibody. The developed ELISA 
detects DDT protein in a range of 100 – 5000 pg/ml, and shows no 
measureable cross reactivity with MIF (Fig. 39).  
 
 
Fig. 39: Specific detection of DDT protein in a newly established ELISA.  A) 
ELISA plate was coated with polyclonal anti-DDT antibody (15 µg/ml). After incubation 
with blocking solution, either DDT or MIF protein was added in a range of 100 – 5000 
pg/ml. For the detection of proteins, first biotinylated anti-DDT, then a streptavidin-HRP 
conjugate was added to the plate. Protein concentration was detected by colorimetric 
measurement of TMB conversion.  B) DDT ELISA does not significantly cross react with 
mouse MIF. A microtiter plate was coated with anti-DDT antibody and either DDT alone 
(100 – 5000 pg/ml) or DDT (100 – 5000 pg/ml) plus 50 ng/ml MIF was added. Protein was 
detected by colorimetric measurement at 450 nm.  
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3.2.3 DDT is released from macrophages 
To date, little is known about the biological function of DDT. Both MIF 
and DDT are leaderless proteins, and it was of interest to analyze whether 
DDT like MIF is released from cells in response to a pro-inflammatory 
stimulus. Fig. 40 illustrates that not only MIF, but also DDT is released 
from bone marrow-derived macrophages in response to LPS.  
 
 
 
Fig. 40: Release of DDT and MIF in response to LPS. Bone marrow-derived 
macrophages were stimulated with LPS (1 µg/ml) ore PBS (control). At the indicated time 
points, supernatants were collected and assayed for DDT and MIF by specific ELISA. The 
results are representative for three independent experiments.  
 
 
The pattern of release of DDT and MIF after stimulation with LPS is very 
similar. Both proteins peak at 16 h, exhibiting a bell-shaped curve often 
observed for released cytokines.  
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3.2.4 Effect of mif-gene deletion on DDT production 
Both MIF and DDT contribute to the secretion of CXCL8 and VEGF (72) 
and both proteins are released in response to LPS stimulation of 
macrophages. Given these overlapping functions of the two proteins it was 
considered that a loss of the mif-gene might be compensated by higher 
expression levels of DDT. Therefore, the intracellular DDT concentration 
in wildtype and mif-/- macrophages was measured (Fig. 41, A), but no 
difference was observed. These results were also reflected when comparing 
DDT concentration in serum of wildtype vs. mif-/- mice (Fig. 41, B). Last, it 
was analyzed whether the deletion of the mif-gene had an effect on the 
stimulated release of DDT, but again no difference between wildtype and 
mif-/- macrophages was measurable (Fig. 41, C).  
 
 
 
Fig. 41: Comparison of DDT production. A) Bone-marrow derived macrophages of 
wildtype (mif+/+) and MIF knockout (mif-/-) were lysed and DDT concentration was 
measured by ELISA, total protein concentration was analyzed using Bradford, (N=8 mice 
per group). B) Serum samples of mif+/+ and mif-/- were collected, and DDT concentration 
was analyzed by Bradford (N=6 mice per group).  C) Bone-marrow derived macrophages 
of wildtype (mif+/+) and MIF knockout (mif-/-) were stimulated with LPS (1 µg/ml) or 
control (PBS). At the indicated time points, supernatants were collected and assayed for 
DDT and MIF by specific ELISA. The results are representative for three independent 
experiments.  
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The functional role of DDT is still unclear. In general DDT might either 
have similar functions as MIF, thus supporting MIF in its pro-
inflammatory, anti-apoptotic role or it might be a counter-regulator of 
MIF, attenuating the effects of MIF.  
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4 Discussion 
4.1 Role of p115 in MIF Secretion 
Macrophage migration inhibitory factor plays an important upstream role 
in the regulation of diverse cellular responses (8, 151, 152) and its role in 
human pathology has been emphasized by the finding that high 
expression MIF alleles are associated with the incidence or the severity of 
inflammatory and oncologic diseases (12-14, 153).   
MIF is constitutively expressed in a large number of tissues, 
predominantly in those that are in contact with the host’s environment. 
(19, 154, 155). The release of MIF, especially from immune cells, occurs in 
many inflammatory diseases, but the precise mechanism underlying the 
secretion of MIF, which lacks an amino-terminal signal sequence, has 
remained enigmatic (4, 5). MIF has been reported to be associated with 
vesicles (134-136), and its release from stimulated monocytes is reduced 
by glyburide and probenicide, which are pharmacological inhibitors mainly 
targeting the ABCA1 transporter (105, 133).  
In many inflammatory diseases, the amount of released MIF positively 
correlates with disease severity, e.g. in sepsis, high MIF levels in the 
serum are in direct relation with a fatal outcome (156-159). Moreover, the 
administration MIF-neutralizing agents such as anti-MIF antibodies or 
the MIF inhibitor ISO-1, were shown to be protective in diverse disease 
models (20, 149). Together, these data clearly demonstrate the importance 
of understanding the molecular mechanisms underlying MIF secretion.    
To this end, a yeast two-hybrid screen was performed to identify 
intracellular proteins that interact with MIF. In this screen, p115 was 
found as a new binding partner of MIF. The specificity of the screen was 
confirmed by the finding that 93% of the specifically interacting clones 
were MIF itself, which associates into a non-covalently associated 
homotrimer (50, 51).  However, a cDNA clone encoding the carboxyl 
terminal 260 amino acids of the Golgi-associated protein p115 also was 
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identified. Co-immunoprecipitation studies confirmed the interaction 
between MIF and p115.  
 
 
4.1.1 MIF is Released from a Pre-Formed Pool 
Lipopolysaccharide (LPS) was one of the first stimuli reported to cause the 
secretion of MIF from cells (5, 8). In order to determine the pathway by 
which MIF is released from immune cells, it was indispensable to 
establish a reliable system to monitor the stimulated release of MIF.  
Monocytes stimulated with LPS effectively release MIF, while the mRNA 
level of both MIF and p115 remain unchanged. These findings are in 
accord with previous observations in murine tissue (19, 140) and clearly 
show that MIF is secreted from pre-formed stores and is not synthesized 
de novo. In contrast, other cytokines, such as TNF-α and IL-1β, show a 
dramatic increase in their mRNA expression level 1 – 3 h post LPS 
stimulation (160, 161). A possible explanation for the difference in mRNA 
expression profiles may be that TNF-α and IL-1β operate exclusively as 
cytokines, whereas MIF has cytokine functions, but in addition also has an 
important intracellular role. For instance, it was reported that MIF 
contributes to cell proliferation via direct interaction with the cell cycle 
regulators p53 and JAB1 (43, 45, 47).  
 
4.1.2 MIF and p115 Associate at the Perinuclear Site  
Previous studies have demonstrated that p115 is localized at the Golgi 
(95). Immunofluorescent microscopy analysis in macrophages showed that 
MIF is localized throughout the cytoplasm, and that MIF and p115 
associate most notably in the area of the Golgi. The comparison of MIF 
and p115 distribution in unstimulated vs. LPS-stimulated macrophages 
furthermore showed that upon stimulation MIF is found predominantly in 
a plasma membrane proximal area, whereas unstimulated cells stain for 
MIF predominantly in the perinuclear ring. p115 is localized at the Golgi, 
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and upon stimulation a portion of p115 is dispersed in the cytoplasm. This 
suggests that the interaction between MIF and p115 occurs early in the 
secretory pathway and that MIF and p115 are co-secreted in vesicles. p115 
may be essential in the transport of MIF from the perinuclear ring to the 
plasma membrane and then out of the cell. This hypothesis is supported 
by data showing a co-secretion of MIF and p115 in LPS stimulated cells.  
It was reported that MIF is detected in vesicles in pituitary cells, cells of 
the testis, and  β-cells of the pancreas (134-136). It is of interest to further 
characterize the location of MIF and p115 in immune cells. Electron 
microscopy images labelled for MIF and p115 might help to understand 
whether MIF and p115 localize together at vesicles or if p115 just 
momentarily associated with MIF, presumably to help transfer MIF into 
vesicles.  
 
 
4.1.3 MIF and p115 Interact Directly 
The interaction between MIF and p115 was discovered in a yeast two-
hybrid screen and affirmed in several co-immunoprecipitation studies in 
mammalian cell systems. Furthermore, the interaction of the two proteins 
was confirmed biochemically in a competition binding assay utilizing 
recombinant MIF and p115702-962. The assay demonstrated that the two 
proteins bind directly and specifically without necessarily requiring 
additional, intermediary proteins for the interaction. The percent of 
competition measured was between 50 and 60%. In contrast, the percent of 
competition reached between MIF and its receptor CD74 is near 100% 
(58).  
A likely explanation for the levelling of the competition curves at 50 – 60% 
is that there is some non-specific background binding to the plate which 
cannot be fully blocked by the Superblock reagent. Alternatively, the 
biotinylated species (both biotin-p115 and biotin-MIF) may have higher 
non-specific binding than the non-modified, native protein. It also is 
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possible that there exist two conformational species of the immobilized 
protein on the plate, and that only one can be competed for.   
  
 
4.1.4 p115 Is Required for the Stimulated Release of MIF 
p115 is a Golgi-associated protein known to be predominantly localized to 
the cis-Golgi and the vesicular tubular clusters (VTC). It was 
demonstrated that the cellular depletion of p115 causes a decrease in MIF 
export from stimulated cells. 
Previous reports describe that the depletion of p115 below detectable 
levels and the microinjection of anti-p115 antibodies causes a 
fragmentation of the Golgi leading to a delay in protein export (101-103, 
162). In contrast, the partial depletion of p115 by the RNAi technique used 
in this study neither affected the structural morphology of the Golgi nor 
reduced the export of ER/Golgi-dependent proteins such as TNF-α, IL-6 
and FGF-4. The release of the unconventionally secreted protein IL-1β, 
which occurs via vesicles (118), and FGF-2, which translocates across the 
plasma membrane (114) also was not affected by a depletion of p115. That 
p115 is necessary for the release of MIF but not other cytokines, whether 
conventionally or unconventionally secreted, suggests a specific and 
unique role in the export of MIF (Fig. 42).  
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Fig. 42: Scheme of p115-dependent MIF secretion. Left: p115 is localized at the cis-
side of the Golgi where it mediates the tethering of vesicles arriving at the Golgi from the 
ER, contributing to the conventional secretion of proteins. MIF and p115 also interact in 
the area of the Golgi. Right: p115 is partially depleted, but still mediates the tethering of 
ER-derived vesicles at the Golgi. MIF is not longer effectively released from cells.  
 
 
The role of p115 in the transfer of vesicles from the ER to the Golgi has 
been established for some time (97). In this process, the carboxy-terminus 
of p115 interacts with the golgin protein GM130 to tether COPII-coated 
vesicles to the cis-side of the Golgi. While the depletion of p115 inhibits 
the stimulated release of MIF, the depletion of GM130 has no measureable 
effect on the release of MIF. This observation indicates that the role of 
p115 in MIF secretion is different from its role in the conventional 
secretion of proteins. To confirm this hypothesis one can analyze the role 
of Rab1, a small GTPase, in the release of MIF, since p115 is a Rab1 
effector protein. The active form of Rab1 binds to the amino-terminal head 
of p115 (96). Rab1 exists in two isoforms, Rab1A and Rab1B; both have 
been suggested to regulate anterograde transport of cargo between the ER 
and the Golgi apparatus (163). Therefore, an efficient knockdown of Rab1 
for a comprehensive study of its role in MIF secretion is difficult to 
accomplish. Another approach to study the effect of Rab1 on MIF release 
is the microinjection of guanine nucleotide dissociation inhibitor (GDI). It 
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was demonstrated that the administration of GDI effectively blocks the 
function of Rab1 by blocking the transfer of stomatitis virus glycoprotein 
(VSV-G) from the ER to the cell surface (164). The disadvantage of this 
approach is that in contrast to the previous studies the conventional 
secretion pathway is compromised; therefore any effect seen after the 
microinjection of GDI could be either contributed to a direct effect on the 
MIF secretion or due to the compromising of the cell system, which then 
secondarily leads to a reduced secretion rate of MIF.  
 
 
4.1.4.1 p115 Overexpression does not Affect MIF Secretion  
For the intracellular binding partner of MIF, JAB1, it was demonstrated 
that both its depletion and its overexpression lead to the modulation of the 
MIF signaling pathway (40, 44).  
While the depletion of p115 consistently decreased MIF release in various 
experimental approaches, the overexpression of p115 had no affect on 
either the stimulated release of MIF or TNF-α. These observations 
indicate that p115 may not be the only limiting factor in the process of 
MIF release, but that other proteins are likely required. To address this 
hypothesis it is of interest to screen for MIF interaction partners in the 
mammalian cell system. Thus far in efforts to identify new MIF binding 
partner only yeast two-hybrid screens were performed. Other approaches, 
like tandem affinity purification (TAP) in the mammalian cell system 
(165) might lead to the discovery of new MIF interaction partners or even 
a multi-protein complex, including MIF and p115, thus possibly 
identifying other proteins involved in the pathway of MIF export.  
 
 
4.1.4.2 MIF and p115 are Co-Secreted 
Macrophages stimulated with LPS export both MIF and p115 in a pattern 
that suggests the coupled release of the two proteins. This observation is 
 Discussion  –  90 
supported by reports linking both MIF (134-136) and p115 (126) to 
vesicles. The co-secretion of the two proteins affirms the previous 
observations that p115 mediates the release of MIF.  
So far it is unknown whether MIF and p115 locate to exosomes in 
macrophages. To address this question, supernatants of stimulated 
macrophages have to be examined. One potential approach is the isolation 
of vesicles by gradient centrifugation and analyzing the vesicles for MIF 
and p115. Another method might be the further examination of the two 
proteins in the supernatant after cross-linking or co-immunoprecipitation. 
A positive outcome of these experiments would support the idea that MIF 
and p115 are released together, possible in exosomes.   
It is also conceivable that p115 mediates a generalized, non-classical 
secretory response by activated monocytes/macrophages that results in the 
release of a p115 macromolecular complex containing numerous proteins, 
of which MIF is one. Further elucidation of both the signals and the 
protein-protein interactions underlying this export pathway may be 
informative and enhance our understanding of the acute secretory 
response of activated monocytes/macrophages.  
  
 
4.1.5 4-IPP Inhibits the Release of MIF and p115 
4-IPP is the first pharmacological inhibitor for MIF found to block the 
secretion of MIF in macrophages in vitro. This was demonstrated via LPS 
stimulation and C. trachomatis infection. Furthermore 4-IPP treatment 
prevents the export of p115 after LPS stimulation, thus affirming the 
hypothesis that MIF and p115 are released in a complex. These data 
identify 4-IPP as a potentially selective inhibitor of the p115/MIF 
secretory pathway. 4-IPP covalently modifies the MIF amino-terminus, 
and alters the protein’s conformational integrity so as to increase its 
binding interaction with p115. One possibility might be that MIF’s 
enhanced binding to p115 in the presence of 4-IPP disrupts its normal 
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trafficking pathway and secondarily reduces MIF secretion. 4-IPP thus 
provides proof-of-concept for the possibility of reducing MIF-dependent 
responses in the earliest phase of cell activation by interfering with MIF’s 
cytoplasmic release.  
The administration of 4-IPP did not improve the survival in a murine 
model of LPS shock. Furthermore, 4-IPP did not reduce the serum level of 
MIF and other cytokines downstream of MIF in response to LPS shock.  
Numerous possibilities might explain why 4-IPP blocks MIF secretion in 
vitro, while it does not inhibit MIF release in vivo. 4-IPP is a highly 
lipophilic reagent; due to its hydrophobic properties, 4-IPP easily crosses 
the plasma membrane, but the solubility in hydrophilic solvents in 
concentrations necessary for an in vivo administration is unsatisfactory. 
Both MIF inhibitors, 4-IPP and ISO-1, are first dissolved in DMSO, but 
while ISO-1 is diluted in water for the intraperitoneal injection, 4-IPP has 
to be diluted in corn oil to avoid precipitation. Mitchell and colleagues are 
in the process of modifying 4-IPP to improve its solubility in water, and it 
is of interest whether a decreased hydrophobicity provides protection in 
the LPS shock model. Variables, such as the time point and dose of 4-IPP 
administration also contribute to the outcome of the experiment. In this 
study, 4-IPP was injected 1.5 h prior to LPS, likewise to the protocol for 
the administration of neutralizing antibody and ISO-1 (5, 20). In contrast 
to neutralizing antibody or ISO-1, it is not known whether 4-IPP 
interferes with MIF’s ability to interact with its receptor CD74, thus a 
different time point of administration might be favourable. Once the 
solubility of the compound is improved, various concentrations and time 
points of administration should to be tested. Furthermore, in the LPS-
shock model, MIF is not only released by specific secretion, but also due to 
cell death, and this latter source of MIF cannot be blocked by 4-IPP. 
Nevertheless, inhibitors such as 4-IPP may be attractive in clinical 
application in those settings, such as severe inflammation, in which rapid 
intervention is desired to prevent the initiation of a tissue-damaging, 
cytokine cascade (166).   
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4.2 The Structural Homologue DDT 
Most cytokines, such as IL-1, belong to large superfamilies. MIF has no 
cytokine family, and its protein family comprises only a few members: D-
dopachrome tautomerase in eukaryotes and the two bacterial proteins 4-
oxalocrotonate tautomerase (4-OT) and 5-carboxymethyl-2-hydroxy-
muconate isomerase (CHMI) (167).  
The members of the MIF/tautomerase superfamily all possess a 
tautomerase active site that has its catalytic base in the amino-terminal 
proline-1. To date, the physiological function for this enzymatic activity is 
unknown, but in the case of MIF, several biological functions are linked to 
this region (61).  
The three-dimensional structures of human MIF and DDT are highly 
conserved; the protomeric polypeptides of the two proteins consist of six β-
strands and two α-helixes. Four of the β-strands form a β-sheet; the 
remaining two β-strands are important for the formation of the trimer by 
forming hydrogen bonds to the adjacent protomers (50, 69) (Fig. 1 and Fig. 
5). However, while the knowledge about MIF’s prominent role as regulator 
of the innate and adaptive immunity has grown tremendously over the 
last decades, nothing is known about the physiological role of DDT. 
In order to establish the basic tools for a better understanding of the 
biological functions of DDT, the native, recombinant protein was purified 
and the first specific polyclonal antibody targeting murine DDT was 
produced. This antibody does not show any cross reactivity to MIF. 
Utilizing this new antibody, an indirect ELISA for DDT was successfully 
developed and used to analyze the release of DDT after stimulation of 
macrophages with LPS. Both DDT and MIF are secreted from cells in 
response to LPS. Additionally it was shown that both proteins are released 
constitutively at a low level. However, herein the molecular cascade 
triggered by DDT after its release in response to a pro-inflammatory 
stimulus was not addressed. Detailed studies have to be conducted to 
elucidate whether DDT exerts similar biological activities than MIF, or 
whether it acts as a cross-regulator of MIF. Both scenarios are well 
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documented in immunology. For instance, the chemokines CXCL9, 
CXCL10, and CXCL11 all bind to the same receptor CXCR3 eliciting an 
increase in intracellular Ca2++ level and activating phosphoinositide-3 and 
MAPK kinase (168).  
Some arguments can be made supporting the hypothesis that MIF and 
DDT share some biological abilities. First, the mRNA and protein levels of 
DDT are unchanged in mif knockout cells compared to wildtype control 
cells. Second, MIF and DDT are released together after stimulation with 
LPS from macrophages. Third, the depletion of either MIF or DDT by 
siRNA results in similar effects (transcriptional regulation of IL-8), both 
involving the receptor CD74 (72).  
With the help of the purified, native DDT protein and anti-DDT antibody, 
future experiments can be performed to further address these questions. 
Additionally, on a molecular level, the details of the release of DDT have 
not been addressed. Established protocols from this work might aid in the 
determination whether the release of DDT also depends on p115, and 
considering the structural conservation of the active sites, whether the 
secretion can also be inhibited by the small molecule inhibitor 4-IPP.  
Anti-MIF therapies have been shown to be beneficial in many 
inflammatory diseases. However, these approaches might not be complete 
without considering DDT’s possible role in disease development, therefore 
studying the molecular mechanisms underlying DDT might improve 
established anti-MIF treatments of inflammatory disease. 
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5 Summary and Outlook 
Macrophage migration inhibitory factor is a pro-inflammatory cytokine 
that plays a pivotal role in the pathogenesis of inflammatory disease such 
as septic shock and rheumatoid arthritis. The release of MIF from 
inflammatory cells is a common feature in these diseases, and a 
correlation between the severity of disease and MIF production is 
observed. MIF is a leaderless protein that is secreted from cells by a 
specialized, non-classical export pathway, possibly involving the 
transporter ABCA1. The release of MIF nevertheless is tightly regulated 
with respect to its production in response to different inflammatory, 
proliferative, and activating stimuli. In recent studies it was demonstrated 
that the administration of neutralizing anti-MIF antibodies and small 
molecule MIF inhibitors is advantageous in inflammatory diseases. These 
approaches have in common that they all target MIF only after it is 
released from cells. A more effective approach in treating MIF-related 
diseases may be to target MIF before it is released from cells. The 
unconventional secretion pathway of MIF might permit to specifically 
block the release of MIF without compromising the general secretion 
mechanism of the cell. To date, little is known about the molecular 
mechanisms involved in the release of MIF.  
My thesis demonstrates that MIF associates with the novel MIF 
interaction partner p115, a Golgi-associated protein that takes part in the 
ER/Golgi secretion pathway. By confocal microscopy, I was able to 
demonstrate that MIF and p115 are associating in the cytoplasm; 
following activation, macrophages redistribute MIF to the plasma 
membrane together with a portion of p115. This finding agrees with 
results obtained from Western blot and ELISA analysis, demonstrating 
that upon LPS stimulation both MIF and p115 are co-secreted, 
accompanied by a corresponding decrease in intracellular protein 
concentration. Accordingly, I demonstrated that the depletion of p115 from 
monocytes/macrophages by RNAi results in an inhibition of MIF release 
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after LPS stimulation. Intriguingly, the secretion of other pro-
inflammatory cytokines, both conventionally released (TNF-α, IL-6) and 
unconventionally released (IL-1β) was not affected by the partial depletion 
of p115. Similarly, the depletion of p115 in HeLa cells did not affect the 
conventional (FGF-4) or unconventional (FGF-2) secretion. This 
observation leads to the assumption that it is possible to specifically target 
the secretion of MIF without compromising the normal and necessary 
secretory mechanism of cells. It is important to note that the effect of p115 
depletion on MIF secretion was not only observed after LPS stimulation, 
but also after bacterial infection with Chlamydia trachomatis. Notably, 
the prototypic small molecule MIF inhibitor, 4-iodo-6-phenylpyrimidine, 
inhibits MIF secretion by targeting the interaction between MIF and p115. 
My data reveal p115 to be a critical intermediary component in the 
regulated secretion of MIF from monocytes/macrophages.  
After the discovery of GRASP65 in the unconventional secretion of acyl-
CoA binding protein in Dictyostelium (169), p115 is the second protein of 
the Golgi complex attributed with a dual function in secretion. On one 
hand p115 is involved in the classical secretion pathway tethering vesicles 
arriving from the ER to the Golgi, and on the other hand it is involved in 
the unconventional secretion of MIF. The discovery that 4-IPP specifically 
blocks the secretion of MIF by interfering with MIF’s interaction with 
p115 gives hope in the search of a potent approach in treating MIF-related 
diseases by blocking its release from cells. It seems feasible to perform a 
screening of MIF inhibitors that specifically target MIF’s ability to 
interact with p115 and block its release from cells.  
 
In addition, in my thesis I report on the initial characterization of the 
structural homolog of MIF, D-dopachrome tautomerase (DDT). After the 
successful purification of recombinant, native murine DDT, a specific anti-
DDT antibody was produced and utilized for the establishment of a DDT-
specific ELISA. It was shown that DDT is released from macrophages in 
response to LPS in a pattern similar to that of MIF. Furthermore, it was 
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shown that the deletion of the mif gene has no effect on the production of 
DDT. The precise biological function of DDT remains unclear and the 
detailed characterization of the secretion pathway of DDT was beyond the 
scope of this thesis, but the comparable release patterns of MIF and DDT 
suggest related functions of the two proteins.  
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